Edgar Filing: OMNICOMM SYSTEMS INC

omcm_10q-063011.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 10-Q

[Mark One]

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2011

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from _______ to ________

Commission File Number: 0-25203

OmniComm Systems, Inc.
(Exact name of registrant as specified in its Charter)


Delaware	11-3349762
(State or other jurisdiction of Incorporation or organization)	(IRS Employer Identification Number)

2101 W. Commercial Blvd. Suite 3500, Ft. Lauderdale, FL	33309
Address of principal executive offices	Zip Code

954.473.1254
(Registrant’s Telephone Number including area code)

No Changes

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer (Do not check if smaller reporting company)	[ ]	Smaller reporting company	[√]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The number of shares outstanding of each of the issuer’s classes of common equity as of August 5, 2011: 86,481,495 common stock $.001 par value.

TABLE OF CONTENTS TO THE QUARTERLY REPORT ON FORM 10-Q FOR THE SIX MONTH PERIOD ENDED JUNE 30, 2011

		Page No.
PART I. - FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations.	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	47
Item 4T	Controls and Procedures.	47
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings.	48
Item 1A.	Risk Factors.	48
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	48
Item 3.	Defaults Upon Senior Securities.	48
Item 4.	Removed and Reserved.	48
Item 5.	Other Information.	48
Item 6.	Exhibits.	48
SIGNATURES

Exhibit 10.45	Promissory Note dated May 13, 2011 to Cornelis F. Wit
Exhibit 31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002– CEO Cornelis F. Wit
Exhibit 31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002– CFO Ronald T. Linares

PART I. FINANCIAL INFORMATION

Item. 1. Financial Statements (unaudited)

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2011			December 31, 2010
	(unaudited)

ASSETS
CURRENT ASSETS
Cash	$	134,445		$	1,213,397
Accounts receivable, net of allowance for doubtful accounts of $269,869 and $269,869 in 2011 and 2010, respectively		1,191,103			1,031,745
Prepaid expenses		119,349			97,337
Total current assets		1,444,897			2,342,479

PROPERTY AND EQUIPMENT, net		857,470			1,046,688

OTHER ASSETS
Intangible assets, net		464,234			696,350
Other assets		35,708			34,218

TOTAL ASSETS	$	2,802,309		$	4,119,735

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	1,538,134		$	1,371,703
Notes payable, current portion		20,000			12,500
Notes payable related parties, current portion		37,500			2,615,000
Deferred revenue, current portion		4,182,449			4,060,425
Conversion feature liability, related parties, current portion		1,457,230			92,134
Conversion feature liability, current portion		36,546			72
Convertible notes payable, current portion, net of discount		75,000			395,733
Convertible notes payable, related parties, current portion, net of discount of $-0- and $399,645, respectively		-0-			2,169,622
Patent settlement liability, current portion		737,499			765,089
Warrant liability, related parties		2,454,194			206,760
Warrant liability		548,996			54,388
Total current liabilities		11,087,548			11,743,426

Notes payable - long term, net of current portion		563,786			601,286
Notes payable related parties, long term, net of current portion, net of discount of $1,080,622 and $-0-, respectively		2,064,757			409,379
Deferred revenue, long term, net of current portion		484,794			691,234
Convertible notes payable, related parties, net of current portion		9,440,000			6,900,000
Convertible notes payable, net of current portion		150,000			-0-
Patent settlement liability - long term, net of current portion		1,598,084			1,588,439

TOTAL LIABILITIES		25,388,969			21,933,764

COMMITMENTS AND CONTINGENCIES (See Note 11)

SHAREHOLDERS' EQUITY (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 share authorized 3,722,500 shares undesignated		-0-			-0-
Series B convertible preferred stock - 230,000 shares authorized, -0- and -0- issued and outstanding, respectively at $.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series C convertible preferred stock - 747,500 shares authorized, -0- and -0- issued and outstanding, respectively at $.001 par value;liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series A convertible preferred stock - 5,000,000 shares authorized, 4,125,224 and 4,125,224 issued and outstanding, respectively at $.001 par value liquidation preference $4,125,224 and $4,125,224, respectively		4,125			4,125
Series D preferred stock - 250,000 shares authorized, 250,000 and 250,000 issued and outstanding, respectively at $.001 par value		250			250
Common stock - 250,000,000 shares authorized, 86,481,495 and 86,081,495 issued and outstanding, respectively, at $.001 par value		86,482			86,082
Additional paid in capital - preferred		4,717,804			4,717,804
Additional paid in capital - common		36,532,989			36,906,356
Less cost of treasury stock: Common - -0- and 1,014,830 shares, respectively		-0-			(503,086	)
Accumulated other comprehensive income (loss)		(35,812	)		(24,298	)
Accumulated deficit		(63,892,498	)		(59,001,262	)
Deferred compensation		-			-
Stock subscriptions receivable		(0	)		(0	)

TOTAL SHAREHOLDERS' (DEFICIT)		(22,586,660	)		(17,814,029	)

TOTAL LIABILITIES AND SHAREHOLDERS'(DEFICIT)	$	2,802,309		$	4,119,735

See accompanying summary of accounting policies and notes to financial statements

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	For the six months ended						For the three months ended
	June 30,						June 30,
	2011			2010			2011			2010
Total revenues	$	6,666,187		$	5,907,352		$	3,351,520		$	3,209,989

Cost of sales		943,972			813,403			497,917			378,532

Gross margin		5,722,215			5,093,949			2,853,603			2,831,457

Operating expenses
Salaries, benefits and related taxes		4,188,364			5,421,648			2,089,623			2,735,898
Rent & occupancy expenses		451,017			434,809			225,980			234,074
Consulting services		152,855			292,377			102,676			81,652
Legal and professional fees		240,795			184,065			104,665			98,549
Travel		247,204			238,955			126,696			113,701
Telephone and internet		116,223			143,307			49,307			60,103
Selling, general and administrative		514,724			709,073			228,758			468,056
Bad debt expense		-0-			13,954			-0-			-0-
Depreciation Expense		241,720			255,342			115,164			129,414
Amortization Expense		232,117			232,117			116,058			116,059
Total operating expenses		6,385,019			7,925,647			3,158,927			4,037,506

Operating loss		(662,804	)		(2,831,698	)		(305,324	)		(1,206,049	)
Other income (expense)
Interest expense		(548,005	)		(1,394,817	)		(276,391	)		(697,552	)
Interest expense, related parties		(725,216	)		(561,284	)		(366,226	)		(288,041	)
Interest income		4,625			48			4,236			1
Change in derivative liabilities		(2,964,751	)		3,483,649			(54,181	)		2,407,655
Other Comprehensive Income (Loss)		4,915			-0-			574			-0-
Income (loss) before income taxes and preferred dividends		(4,891,236	)		(1,304,102	)		(997,312	)		216,014
Net income (loss)		(4,891,236	)		(1,304,102	)		(997,312	)		216,014
Preferred stock dividends
Preferred stock dividends in arrears
Series A Preferred		(102,004	)		(102,004	)		(51,284	)		(51,284	)
Total preferred stock dividends		(102,004	)		(102,004	)		(51,284	)		(51,284	)
Net income (loss) attributable to common stockholders	$	(4,993,240	)	$	(1,406,106	)	$	(1,048,596	)	$	164,730

Net income (loss) per share
Basic and Diluted	$	(0.06	)	$	(0.02	)	$	(0.01	)	$	0.00
Weighted average number of shares outstanding
Basic and Diluted		86,207,462			85,507,699			86,332,044			85,507,699

See accompanying summary of accounting policies and notes to financial statements

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT)
FOR THE PERIOD JANUARY 1, 2010 TO JUNE 30, 2011
(unaudited)
								Preferred Stock
								5% Series A Convertible					8% Series B Convertible					8% Series C Convertible					Series D Preferred Stock
	Common Stock				Additional						Additional					Additional					Additional					Additional					Accumulated Other						Total Shareholders'
	Number	$	0.001		Paid In			Number	$	0.001	Paid In		Number	$	0.001	Paid In		Number	$	0.001	Paid In		Number	$	0.001	Paid In		Accumulated			Comprehensive			Treasury			Equity
	of Shares	Par Value			Capital			of Shares	Par Value		Capital		of Shares	Par Value		Capital		of Shares	Par Value		Capital		of Shares	Par Value		Capital		Deficit			Income			Stock			(Deficit)

Balances at December 31, 2009	85,507,699	$	86,474		$	36,278,798		4,125,224	$	4,125	$	3,718,054	-0-	$	-0-	$	-0-	-0-	$	-0-	$	-0-	-0-	$	-0-	$	-0-	$	(55,870,527	)	$	2,934		$	(503,086	)	$	(16,283,228	)

Employee stock option expense						584,061																																584,061

Common stock issued in lieu of salaries	573,796		574			42,531																																43,105

Adjustment for treasury stock transactions			(966	)		966																																-0-

Foreign currency translation adjustment																																(27,232	)					(27,232	)

Issuance of Series D preferred stock																							250,000		250		999,750											1,000,000

Correcting entry to retained earnings																																						-0-

Net loss for the period ended December 31, 2010	-		-			-		-		-		-	-		-		-	-		-		-	-		-		-		(3,130,735	)		-			-			(3,130,735	)

Balances at December 31, 2010	86,081,495		86,082			36,906,356		4,125,224		4,125		3,718,054	-		-		-	-		-		-	250,000		250		999,750		(59,001,262	)		(24,298	)		(503,086	)		(17,814,029	)

Employee stock option expense						90,119																																90,119

Treasury stock retired						(503,086	)																												503,086			-0-

Foreign currency translation adjustment																																(11,514	)					(11,514	)

Issuance of common stock in lieu of salary	400,000		400			39,600																																40,000

Net loss for the period ended June 30, 2011	-		-			-		-		-		-	-		-		-	-		-		-	-		-		-		(4,891,236	)		-			-			(4,891,236	)

Balances at June 30, 2011	86,481,495	$	86,482		$	36,532,989		4,125,224	$	4,125	$	3,718,054	-0-	$	-0-	$	-0-	-0-	$	-0-	$	-0-	250,000	$	250	$	999,750	$	(63,892,498	)	$	(35,812	)	$	-0-		$	(22,586,660	)

See accompanying summary of accounting policies and notes to financial statements

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
	For the six months ended
	June 30,
	2011			2010

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(4,891,236	)	$	(1,304,102	)
Adjustment to reconcile net loss to net cash (used in) operating activities
Change in derivative liabilities		2,964,751			(3,483,649	)
Interest expense from derivative instruments		497,884			1,342,953
Common stock issued in lieu of salary		40,000			-0-
Employee stock option expense		90,119			357,684
Depreciation and amortization		473,837			487,459
Bad debt expense		-0-			13,954
Changes in operating assets and liabilities
Accounts receivable		(159,358	)		(428,084	)
Prepaid expenses		(22,015	)		(15,462	)
Other assets		(1,490	)		(28,122	)
Accounts payable and accrued expenses		211,431			247,213
Patent settlement liability		(17,944	)		16,842
Deferred revenue		(84,415	)		2,451,436
Net cash (used in) operating activities		(898,436	)		(341,878	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(52,502	)		(218,218	)
Net cash used in investing activities		(52,502	)		(218,218	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, related parties		96,000			565,000
Repayments of notes payable		(212,500	)		-0-
Net cash provided by (used in) financing activities		(116,500	)		565,000

Effect of exchange rate changes on cash and cash equivalents		(11,514	)		(22,778	)
Net (decrease) in cash and cash equivalents		(1,078,952	)		(17,874	)
Cash and cash equivalents at beginning of period		1,213,397			60,352

Cash and cash equivalents at end of period	$	134,445		$	42,478

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Income taxes	$	-0-		$	-0-
Interest	$	525,731		$	570,242

Non-cash transactions
Notes payable issued in exchange for existing notes payable	$	2,866,879		$	-0-
Notes payable issued for accounts payable	$	45,000		$	-0-

See accompanying summary of accounting policies and notes to financial statements

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 1:

ORGANIZATION AND NATURE OF OPERATIONS

OmniComm Systems, Inc. (“OmniComm” or the “Company”) is a healthcare technology company that provides Web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations, and other clinical trial sponsors principally located in the United States and Europe. Our proprietary EDC software applications: TrialMaster®; TrialOne®; and eClinical Suite, allow clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data.

Our ability to compete within the EDC industry is predicated on our ability to continue enhancing and broadening the scope of solutions offered through our EDC software and services. Our research and development efforts are focused on developing new, complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. The majority of our research and development activities represent salaries to our software developers. During the six months ended June 30, 2011 and June 30, 2010 we spent approximately $1,280,630 and $1,844,866, respectively, on research and development activities, which is primarily comprised of payroll and related costs associated with the development of our software products.

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’ Annual Report filed on Form 10-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

UNAUDITED FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the consolidated financial statements have been condensed or omitted. The results for the periods indicated are unaudited, but reflect all adjustments (consisting only of normally recurring adjustments) which management considers necessary for a fair presentation of operating results.

The operating results for the six month period ended June 30, 2011 are not necessarily indicative of the results that may be expected for the year-ended December 31, 2011. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2010.

ESTIMATES IN FINANCIAL STATEMENTS

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities and the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results may differ from those estimates.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

RECLASSIFICATIONS

Certain reclassifications have been made in the 2010 financial statements to conform to the 2011 presentation. These reclassifications did not have any effect on our net loss or shareholders’ deficit.

FOREIGN CURRENCY TRANSLATION

The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters—Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currencies of the Company’s subsidiaries, OmniComm Europe GmbH and OmniComm Ltd., in Germany and the United Kingdom, are the Euro and British Pound Sterling, respectively. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded $11,514 and $20,466 of net translation losses for the six months ended June 30, 2011 and June 30, 2010, respectively.

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne and eClinical Suite (the “EDC Software”). Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in one reportable segment which is the delivery of EDC services and products to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues. Accordingly, revenues are currently generated through four main activities. These activities include hosted applications, licensing, professional services and maintenance.

Hosted Application Revenues

The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard Web-browser, with customer support and training services. The Company's TrialOne solution is presently available only on a licensed basis. To date, hosted solutions have been related primarily to TrialMaster.

Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial: the first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The second component involves application hosting and related support services as well as billing change orders which consist of amounts billed to customers for functionality changes made; and the third stage involves services required to close out, or lock, the database for the clinical trial.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

Fees charged and costs incurred for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the second stage are generally billed quarterly in advance. Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Services for this offering are generally charged as a fixed fee payable on a quarterly or annual basis. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software. From time-to-time a client might require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for 3 to 5 year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days.

In the past the Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may in the future do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base.

Maintenance Revenues

Maintenance includes telephone-based help desk support and software maintenance. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

Professional Services

The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces and running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The fees associated with each business activity for the six months ended June 30, 2011 and June 30, 2010, respectively are:

	For the six months ended
Business Activity	June 30, 2011		June 30, 2010
Set-up Fees	$	1,586,262	$	2,115,769
Change Orders		160,902		81,546
Maintenance		2,764,632		2,149,614
Software Licenses		1,617,406		742,202
Professional Services		242,703		456,499
Hosting		294,282		361,722
Totals	$	6,666,187	$	5,907,352

COST OF REVENUES

Cost of revenues primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s professional services staffs. Cost of revenues also includes outside service provider costs, data center and networking expenses, and allocated overhead. These costs are expensed as incurred.

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

ACCOUNTS RECEIVABLE

Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectibility of accounts receivable and prior bad debt experience. The Company had recorded an allowance for uncollectible accounts receivable of $269,869 as of June 30, 2011 and December 31, 2010, respectively.

The following table summarizes activity in the Company's allowance for doubtful accounts for the years presented.

	For the periods ended
	June 30, 2011		December 31, 2010
Beginning of period	$	269,869	$	267,526
Bad debt expense		-0-		13,954
Write-offs		-0-		(11,611	)
End of period	$	269,869	$	269,869

CONCENTRATION OF CREDIT RISK

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of June 30, 2011, there were no balances of cash and cash equivalents which were deposited in excess of FDIC-insured limits.

Except as follows, the Company has no significant off-balance-sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States and Europe. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of June 30, 2011. Prior to 2008 the Company had not historically experienced significant losses related to receivables from individual customers or groups of customers in any specific industry or geographic area. During the second half of fiscal 2008 and continuing during 2009, the biotechnology industry experienced liquidity and funding difficulties. Several of the Company’s clients operate in this segment. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses when incurred are charged to the allowance. The Company's losses related to collection of accounts receivable prior to fiscal 2008 were consistently within management's expectations. The overall downturn in the Global economy impacted several of the Company’s clients beginning in late 2008. During 2011 the Company has seen increased activity in the biotechnology sector and believes that some of the credit and financial constraints that were limiting R & D activity have begun to decrease. Due to these factors, the Company believes no additional credit risk beyond the amounts provided for in our allowance for uncollectible accounts, which the Company reevaluates on a monthly basis based on specific review of receivable agings and the period that any receivables are beyond the standard payment terms, is believed by management to be probable in the Company's accounts receivable. The Company does not require collateral from its customers in order to mitigate credit risk.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

One customer accounted for 20% of our revenues during the six months ended June 30, 2011 or approximately $1,312,808. One customer accounted for 22% of our revenues during the six months ended June 30, 2010 or approximately $1,298,531. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the six month periods presented.

	Revenues					Accounts Receivable
For the Period ended	# of Customers		Percentage of Total Revenues			# of Customers		Percentage of Accounts Receivable
June 30, 2011		1		20	%		4		54	%
December 31, 2010		1		20	%		3		44	%
June 30, 2010		1		22	%		3		34	%

Subsequent to two acquisitions completed in fiscal 2009, the Company’s European operations have become a more material portion of its overall revenues. The table below provides revenues from European customers for the six month periods ended June 30, 2011 and June 30, 2010, respectively.

European Revenues
for the six months ended
June 30, 2011					June 30, 2010
European Revenues		% of Total Revenues			European Revenues		% of Total Revenues
$	1,384,507		20.8	%	$	745,718		12.6	%

The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with ASC 805- Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our unaudited condensed consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information.

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

DEFERRED REVENUE

Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of June 30, 2011, the Company had $4,667,243 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to 5 years. The Company had $4,182,449 in deferred revenues that are expected to be recognized in the next twelve months.

ADVERTISING

Advertising costs are expensed as incurred. Advertising costs were $158,764 and $161,516 for the six months ended June 30, 2011 and June 30, 2010, respectively and are included under selling, general and administrative expenses on our Unaudited Condensed Consolidated Statements of Operations.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

RESEARCH AND DEVELOPMENT EXPENSES

Software development costs are included in research and development and are expensed as incurred. ASC 985.20, Software Industry Costs of Software to Be Sold, Leased or Marketed, requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC 985.20. During the six month ended June 30, 2011 and June 30, 2010 we spent approximately $1,280,630 and $1,844,866 respectively, on research and development activities, which include costs associated with the development of our software products and services for our client’s projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants. Research and development costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

EMPLOYEE EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009. The 2009 Plan provides for the issuance of up to 7.5 million shares to employees, directors and key consultants in accordance with the terms of the 2009 Plan documents. The predecessor plan, the OmniComm Systems, Inc., 1998 Stock Incentive Plan (the “1998 Plan”) expired on December 31, 2008. The 1998 Plan provided for the issuance of up to 12.5 million shares in accordance with the terms of the 1998 Plan document. Each plan is more fully described in “Note 13, Employee Equity Incentive Plans.” The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions.

ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Unaudited Condensed Consolidated Statements of Operations. The Company currently uses the American Binomial option pricing model to determine grant date fair value.

EARNINGS PER SHARE

The Company accounts for Earnings Per Share using ASC 260 – Earnings per Share. Unlike primary earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities.

INCOME TAXES

The Company accounts for income taxes in accordance ASC 740, Income Taxes. ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws.

Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

IMPACT OF NEW ACCOUNTING STANDARDS

During fiscal 2011, we adopted the following new accounting pronouncements:

In December 2010, the FASB issued ASU 2010-29, “Business Combinations (Topic 805): Disclosure of supplementary pro forma information for business combinations.” This update changes the disclosure of pro forma information for business combinations. These changes clarify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. Also, the existing supplemental pro forma disclosures were expanded to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. These changes became effective for the Company beginning January 1, 2011. The Company’s adoption of this update did not have an impact on the Company’s financial condition or results of operations.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

In December 2010, the FASB issued ASU 2010-28, “Intangible –Goodwill and Other (Topic 350): When to perform Step 2 of the goodwill impairment test for reporting units with zero or negative carrying amounts.” This update requires an entity to perform all steps in the test for a reporting unit whose carrying value is zero or negative if it is more likely than not (more than 50%) that a goodwill impairment exists based on qualitative factors, resulting in the elimination of an entity’s ability to assert that such a reporting unit’s goodwill is not impaired and additional testing is not necessary despite the existence of qualitative factors that indicate otherwise. These changes became effective for the Company beginning January 1, 2011. The adoption of this ASU did not have a material impact on our financial statements.

In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement (Topic 820) — Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs (“ASU 2011-04”), which clarifies the wording and disclosures required in Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), to converge with those used (to be used) in International Financial Reporting Standards (“IFRS”). The update explains how to measure and disclose fair value under ASC 820. However, the FASB does not expect the changes in this standards update to alter the current application of the requirements in ASC 820. The provisions of ASU 2011-04 are effective for public entities prospectively for interim and annual periods beginning after December 15, 2011. Early adoption is prohibited. Therefore, ASU 2011-04 is effective for the Company during the first quarter of fiscal 2012. The Company does not expect ASU 2011-04 to have a material effect on the Company’s results of operations, financial condition, and cash flows.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements that have been issued since the filing of our Form 10-K for the year ended December 31, 2010 to determine their impact, if any, on our financial statements.

NOTE 3: GOING CONCERN

We have experienced net losses and negative cash flow from operations and have funded our activities to-date primarily from debt and equity financings. We will continue to require substantial funds to continue our research and development activities and to market, sell and commercialize our technology. We may need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our research and development activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; and other changes in economic, regulatory or competitive conditions in our planned business.

Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the research and development programs relating to our technology can be conducted at projected costs and that progress towards the commercialization of our technology will be timely and successful. There can be no assurance that changes in our research and development plans, acquisitions or other events will not result in accelerated or unexpected expenditures.

To satisfy our capital requirements, we may seek additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development and marketing programs. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock or result in increased interest expense in future periods.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The ability of the Company to continue in existence is dependent on its having sufficient financial resources to bring products and services to market for marketplace acceptance. As a result of our historical operating losses, negative cash flows and accumulated deficits for the period ending June 30, 2011 there is substantial doubt about the Company’s ability to continue as a going concern.

The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 4: EARNINGS PER SHARE

Basic earnings (loss) per share were calculated using the weighted average number of shares outstanding of 86,207,462 and 85,507,699 for the six months ended June 30, 2011 and June 30, 2010, respectively.

Basic earnings (loss) per share were calculated using the weighted average number of shares outstanding of 86,332,044 and 85,507,699 for the three months ended June 30, 2011 and June 30, 2010, respectively.

Antidilutive shares aggregating 93,647,034 and 83,671,745 have been omitted from the calculation of dilutive EPS for the six month and three months ended June 30, 2011 and June 30, 2010, respectively as the shares were antidilutive. Provided below is reconciliation between numerators and denominators of the basic and diluted earnings per shares: There were no differences between basic and diluted earnings per share. The table below provides a reconciliation of anti-dilutive securities outstanding as of June 30, 2011 and June 30, 2010, respectively.

Anti-Dilutive Security	June 30, 2011		June 30, 2010
Preferred stock		2,750,149		2,750,149
Employee stock options		12,739,500		12,286,500
Warrants		52,195,758		40,808,241
Convertible notes		24,620,000		27,200,000
Shares issuable for accrued interest		1,341,627		626,855

Total		93,647,034		83,671,745

The employee stock options are exercisable at prices ranging from $0.10 to $0.70 per share. The exercise price on the stock warrants range from $0.25 to $0.60 per share. Shares issuable upon conversion of Convertible Debentures have conversion prices ranging from $0.25 to $0.50 per share.

The Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net loss per share and were not included in the computation of diluted earnings per share.

For the six months ended
	June 30, 2011								June 30, 2010
	Income (loss)			Shares		Per-Share			Income (loss)			Shares		Per-Share
	Numerator			Denominator		Amount			Numerator			Denominator		Amount
Basic EPS	$	(4,993,240	)		86,207,462	$	(0.06	)	$	(1,406,106	)		85,507,699	$	(0.02	)

Effect of Dilutive Securities
None.		-0-			-0-		-0-			-0-			-0-		-0-
Diluted EPS	$	(4,993,240	)		86,207,462	$	(0.06	)	$	(1,406,106	)		85,507,699	$	(0.02	)


For the three months ended
	June 30, 2011								June 30, 2010
	Income (loss)			Shares		Per-Share			Income (loss)			Shares		Per-Share
	Numerator			Denominator		Amount			Numerator			Denominator		Amount
Basic EPS	$	(1,048,596	)		86,332,044	$	(0.01	)	$	164,730			85,507,699	$	0.00

Effect of Dilutive Securities
None.		-0-			-0-		-0-			-0-			-0-		-0-
Diluted EPS	$	(1,048,596	)		86,332,044	$	(0.01	)	$	164,730			85,507,699	$	0.00

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 5: PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

	June 30, 2011						December 31, 2010
	Cost		Accumulated Depreciation		Net Book Value		Cost		Accumulated Depreciation		Net Book Value		Estimated Useful Lives
Computer & Office Equipment	$	1,504,549	$	1,006,356	$	498,193	$	1,466,187	$	914,016	$	552,171	5 Years
Leasehold Improvements		75,476		56,738		18,738		84,313		51,212		33,101	5 Years
Computer Software		1,393,501		1,080,764		312,737		1,366,955		937,141		429,814	3 Years
Office Furniture		107,687		79,885		27,802		106,759		75,157		31,602	5 Years
	$	3,081,213	$	2,223,743	$	857,470	$	3,024,214	$	1,977,526	$	1,046,688

Depreciation expense for the six months ended June 30, 2011 and June 30, 2010 was $241,720 and $255,342 respectively.

NOTE 6: INTANGIBLE ASSETS, AT COST

Intangible assets consists of the following:

	June 30, 2011						December 31, 2010
Asset	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Depreciation		Net Book Value		Estimated Useful Lives
Customer lists	$	1,392,701	$	928,467	$	464,234	$	1,392,701	$	696,351	$	696,350	3 Years
	$	1,392,701	$	928,467	$	464,234	$	1,392,701	$	696,351	$	696,350

Amortization expense was $232,117 and $232,117 for the six months ended June 30, 2011 and June 30, 2010, respectively.

Annual amortization expense for the Company’s intangible assets is as follows:

2011	$	232,117
2012		232,117
2013		-0-
2014		-0-
2015		-0-

Total	$	464,234

NOTE 7: ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

Account	June 30, 2011		December 31, 2010
Accounts payable	$	561,342	$	629,775
Accrued payroll and related costs		271,409		179,331
Other accrued expenses		52,463		159,294
Accrued interest		652,920		403,303

Total Accounts Payable and Accrued Expenses	$	1,538,134	$	1,371,703

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 8: NOTES PAYABLE

At June 30, 2011, the Company owed $3,766,665 in notes payable all of which are unsecured. The table below provides details as to the terms and conditions of the notes payable.


							Non-Related Party				Related Party
					Ending												Total		Discount at
Origination Date	Maturity Date	Interest Rate			Principal 6/30/2011		Current		Long Term		Current		Long Term		Allocated Discount		Discount Amortized		June 30, 2011
12/31/2010	7/1/2012		12	%	$	51,800	$	-0-	$	51,800	$	-0-	$	-0-	$	-0-	$	-0-	$	-0-
12/31/2010	7/1/2012		12	%		60,000		-0-		60,000		-0-		-0-		-0-		-0-		-0-
2/1/2011	4/1/2013		12	%		137,500		-0-		-0-		-0-		137,500		-0-		-0-		-0-
4/1/2011	10/1/2012		12	%		45,000		-0-		-0-		-0-		45,000		-0-		-0-		-0-
12/31/2010	12/31/2011		12	%		20,000		-0-		-0-		20,000		-0-		-0-		-0-		-0-
12/31/2010	4/1/2012		12	%		37,500		37,500		-0-		-0-		-0-		-0-		-0-		-0-
12/16/2010	12/16/2012		12	%		20,000		-0-		20,000		-0-		-0-		-0-		-0-		-0-
12/31/2010	1/1/2013		10	%		308,561		-0-		308,561		-0-		-0-		-0-		-0-		-0-
12/31/2010	1/1/2013		10	%		123,425		-0-		123,425		-0-		-0-		-0-		-0-		-0-
3/31/2011	4/1/2014		12	%		2,866,879		-0-		-0-		-0-		2,866,879		1,178,861		98,239		1,080,622
5/13/2011	1/1/2013		12	%		96,000		-0-		-0-		-0-		96,000		-0-		-0-		-0-

					$	3,766,665	$	37,500	$	563,786	$	20,000	$	3,145,379	$	1,178,861	$	98,239	$	1,080,622

On March 31, 2011, the Company issued a note payable in the principal amount of $2,866,879 and warrants to purchase 11,467,517 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of March 31, 2016 to our Chief Executive Officer, Cornelis F. Wit. The note accrues interest at a rate of 12% per annum and has a maturity date of April 1, 2014. This issuance caused us to calculate and record a derivative liability for the extension of the derivative liability. The warrants were valued using a Binomial option pricing model. A value of $1,178,861 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the recorded discount, the carrying amount of the note at June 30, 2011 was $1,786,257. The warrant liability (discount) will be amortized over the 36 month exercise period of the note payable. The Company will continue to perform a fair value calculation periodically on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

On May 13, 2011, the Company issued a note payable in the principal amount of $96,000 to our Chief Executive Officer, Cornelis F. Wit. The note accrues interest at a rate of 12% per annum and has a maturity date of January 1, 2013.

NOTE 9: CONVERTIBLE NOTES PAYABLE

The following table summarizes the convertible debt outstanding as of June 30, 2011.

																Carrying Amount
						Principal at				Total		Discount at		Carrying Amount at		Short Term				Long Term
Date of Issuance	Interest Rate			Original Principal		June 30, 2011		Allocated Discount		Discount Amortized		June 30, 2011		June 30, 2011		Related		Non Related		Related		Non Related
Aug-01-1999		10	%	$	862,500	$	75,000	$	-0-	$	-0-	$	-0-	$	75,000	$	-0-	$	75,000	$	-0-	$	-0-
Aug-29-2008		10	%		2,270,000		1,920,000		2,052,080		2,052,080		-0-		1,920,000		-0-		-0-		1,920,000		-0-
Dec-16-2008		12	%		5,075,000		4,980,000		1,370,250		1,370,250		-0-		4,980,000		-0-		-0-		4,980,000		-0-
Sep-30-2009		12	%		1,400,000		1,200,000		526,400		526,400		-0-		1,200,000		-0-		-0-		1,100,000		100,000
Dec-31-2009		12	%		1,490,000		1,490,000		935,720		935,720		-0-		1,490,000		-0-		-0-		1,440,000		50,000

Totals				$	11,097,500	$	9,665,000	$	4,884,450	$	4,884,450	$	0	$	9,665,000	$	0	$	75,000	$	9,440,000	$	150,000

The convertible note originally issued on September 30, 2009 was comprised of a principal amount due of $1,400,000 with a maturity date of March 30, 2011. On March 30, 2011, the Company repaid $200,000 of the outstanding principal amounts owed and extended $1,200,000 of the convertible notes until April 1, 2013, including $1,100,000 in convertible notes held by our Chief Executive Officer, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the September 2009 offering. The warrants are now exercisable until September 30, 2015 at an exercise price of $0.25 per share.

The convertible notes originally issued on December 31, 2009 were comprised of a principal amount due of $1,490,000 with a maturity date of June 30, 2011. On June 30, 2011, the Company extended all $1,490,000 of the convertible notes until October 1, 2013, including $1,440,000 in convertible notes held by our Chief Executive Officer, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the December 2009 offering. The warrants are now exercisable until December 31, 2015 at an exercise price of $0.25 per share.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The payments required at maturity under the Company’s outstanding convertible debt at June 30, 2011 are as follows:

2011	$	75,000
2012		-0-
2013		9,590,000
2014		-0-
2015		-0-
Total	$	9,665,000

NOTE 10: FAIR VALUE MEASUREMENT

The Company measures the fair value of its assets and liabilities under the guidance of ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement.

ASC 820 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows:

Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and

Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities.

The valuation techniques that may be used to measure fair value are as follows:

Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities

Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings method

Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost)

The Company also adopted the provisions of ASC 825, Financial Instruments in the first quarter of 2008. ASC 825 allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement, and did not elect the fair value option for any financial assets and liabilities transacted in the year-ended December 31, 2010 and the six months ended June 30, 2011.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The Company’s financial assets or liabilities subject to ASC 820 as of June 30, 2011 include the conversion feature and warrant liability associated with convertible debentures issued during fiscal 2008 and 2009. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC 815. See Note 9 – Convertible Notes Payable.

Following is a description of the valuation methodologies used to determine the fair value of the Company’s financial assets including the general classification of such instruments pursuant to the valuation hierarchy.

A summary of the fair value of liabilities measured at fair value on a recurring basis follows:

	Fair Value		Quoted prices in active markets for identical assets/ liabilities			Significant Other Observable Inputs		Significant Unobservable Inputs
	at June 30, 2011		(Level 1)			(Level 2)		(Level 3)

Derivatives: (1) (2)

Conversion feature liability	$	1,493,776	$	-0-		$	-0-	$	1,493,776

Warrant liability		3,003,190		-0-			-0-		3,003,190

Total of derivative liabilties	$	4,496,966	$	-0-		$	-0-	$	4,496,966

(1) The fair value of the Derivative Instruments was estimated using the Income Approach and using the American Binomial option pricing model with the following assumptions for the three months ended June 30, 2011
(2) The fair value at the measurement date is equal to their carrying value on the balance sheet

Significant Valuation Assumptions of Derivative Instruments at June 30, 2011
Risk free interest rate				0.9	%
Dividend yield				0.00	%
Expected Volatility				133.1	%
Expected life (range in years)
Conversion feature liability			1.76 to 2.47
Warrant liability			0.67 to 4.76

	Other Income
	for the six months ended
	June 30, 2011			June 30, 2010
The net amount of total gains/(losses) for the period included in earnings attributable to the unrealized gain or loss from changes in derivative liabilities at the reporting date	$	(2,964,751	)	$	3,483,649

Total unrealized gains/(losses) included in earnings	$	(2,964,751	)	$	3,483,649

The tables below set forth a summary of changes in fair value of the Company’s level 3 financial liabilities at fair value for the six months ended June 30, 2011. The tables reflect gains and losses for all financial liabilities at fair value categorized as level 3 as of June 30, 2011.

	Level 3 Financial Assets and Financial Liabilities at Fair Value
					Net unrealized (gains)/
					losses relating
					to instruments		Net purchases,
	Balance,				still held at		issuances		Net transfers		Balance,
	Beginning		Net realized		the reporting		and		in and/or out		end of
	of year		gains/(losses)		date		settlements		of level 3		period
Period ended June 30, 2011
Derivatives:

Conversion feature liability	$	92,206	$	-0-	$	1,401,570	$	-0-	$	-0-	$	1,493,776

Warrant liability		261,148		-0-		1,563,181		1,178,861		-0-		3,003,190

Total of derivative liabilties	$	353,354	$	-0-	$	2,964,751	$	1,178,861	$	-0-	$	4,496,966

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 11: COMMITMENTS AND CONTINGENCIES

The Company currently leases office space under operating leases for its office locations and has several operating leases related to computer co-location and disaster recovery for its operations. The minimum future lease payments required under the Company’s operating leases at June 30, 2011 are as follows:

2011	$	257,733
2012		386,378
2013		194,738
2014		189,760
2015		197,350

Total	$	1,225,959

In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the lease. Rent expense was $451,017 and $434,809 for the six months ended June 30, 2011 and June 30, 2010, respectively.

The Company’s corporate office lease expires in September 2016. The Company’s lease on its New Jersey field office expires in February 2013. The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in October 2012. The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Bonn, Germany under the terms of a lease that expires in December 2011. The Company is presently reviewing its options in relation to its office lease in the German office but believes that suitable office space is available at market rates similar to those it currently has.

LEGAL PROCEEDINGS

On November 24, 2010, Achyut Dhakal, a former employee, filed suit in the United States District Court for the Southern District of Florida, Miami Division, alleging racial and national discrimination, retaliation for a requested FMLA leave, retaliation under state whistleblower provisions and monies owed for overtime pay under the Fair Labor Standards Act (FLSA). The Company disagreed with the allegations and submitted its response on February 1, 2011. On March 3, 2011, the Company and Mr. Dhakal, subject to the terms agreed to during a court mandated settlement conference, entered into a Settlement Agreement and Full Release subject to mutual non-disclosure provisions. On March 3, 2011, the Court entered an Order of Dismissal with Prejudice approving the settlement.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

PATENT LITIGATION SETTLEMENT

On April 9, 2009, we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”) which relates to a lawsuit filed on September 18, 2008 in the United States District Court for the District of Maryland by DataSci against OmniComm alleging infringement of a U.S. Patent No. 6,496,827 B2 entitled “Methods and Apparatus for the Centralized Collection and Validation of Geographically Distributed Clinical Study Data with Verification of Input Data to the Distributed System” (“Licensed Patent”) claimed to be owned by DataSci. Pursuant to the agreement, the parties entered into a Stipulated Order of Dismissal of the lawsuit filed by DataSci and DataSci granted us a worldwide, non-exclusive non-transferable right and license under the Licensed Patent, the subject of the claim, and the right to sublicense TrialMaster on a Technology Transfer and Technology Transition basis. The license expressly excludes the right to make, use, sell, import, market, distribute, oversee the operation of, or service systems covered by, a claim (if any) of the Licensed Patent to the extent such systems are used for creating and managing source documentation and conducting remote data validation in clinical trial studies using a tablet PC with stylus, touch screen device, digitizing tablet, digitizer pen, or similar mobile processing device (“Digitizing Device”), wherein the source documentation is electronic and is completed using a Digitizing Device. Under the terms of the license, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein, from January 1, 2009 until the expiration of the Licensed Patent equal to two percent (2%) of OmniComm’s annual Gross Revenues or, alternatively, the annual minimum royalty payment(s), whichever is greater. The remaining minimum royalty payments per year are as follows:

2011	$	737,499
2012		450,000
2013		450,000
2014		450,000
2015		450,000
2016-2017		787,500
Total	$	3,324,999

In conjunction with the acquisition of the eResearch Technology, Inc. EDC assets, the Company entered into the First Amendment to Settlement and Licensing Agreement with DataSci, LLC in June 2009 to provide for license payments totaling $300,000 to DataSci over the next three years for the EDC assets acquired in that transaction. The Company began making annual payments of $100,000 to DataSci beginning in July 2009 and has to-date made payments totaling $200,000 with a final payment of $100,000 due in July 2011.

During the six months ended June 30, 2011 and June 30, 2010, respectively, the Company recorded a charge to earnings of $122,144 and $125,779, respectively, which amounts represent (1) the amount of additional license expense incurred above the stipulated minimum in the DataSci License Agreement during the six month periods ended June 30, 2011 and June 30, 2010 and (2) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

NOTE 12: RELATED PARTY TRANSACTIONS

On February 1, 2011, the Company issued a promissory note for $137,500 to Noesis International Holdings, the parent company of Noesis Capital Corp., the Company’s Placement Agent for several equity and debt transactions from 1999 to 2007 and a significant shareholder in the Company. The amount was borrowed under a promissory note bearing interest at 12% per annum payable with a maturity date of April 1, 2013. The promissory note replaces a promissory note in the same principal amount that matured on January 31, 2011.

On March 30, 2011, the Company extended a convertible note in the principal amount of $1,100,000 held by our Chief Executive Officer, Cornelis F. Wit that had matured on that date. The convertible note which was originally issued on September 30, 2009, bears interest at 12% per annum with interest payable monthly. Mr. Wit extended the maturity date of his convertible note until April 1, 2013 in accordance with the terms of Amendment Number One To Securities Purchase Agreement. We also extended the expiration date of the 4,400,000 warrants issued with convertible note by two years to September 30, 2015.

On March 31, 2011, the Company issued a promissory note in the principal amount of $2,866,879 to our Chief Executive Officer, Cornelis F. Wit. The note carries and interest rate of 12% per annum and is due on April 1, 2014. In addition, the Company issued to Mr. Wit a warrant to purchase 11,467,517 shares of our common stock at an exercise price of $0.25 per share with an expiration date of April 1, 2014. The promissory note consolidates the principal amounts owed under several promissory notes originally issued during 2010. The promissory note is comprised of the following amounts received on the following dates:

Promissory Note issued on April 13, 2010 with a principal amount of $450,000 with a maturity date of December 31, 2010.

ii.

Promissory Note issued on June 29, 2010 with a principal amount of $115,000 with a maturity date of December 31, 2010.

iii.

Promissory Note issued on September 30, 2010 with a principal amount of $695,000 with a maturity date of December 31, 2010.

iv.

Promissory Note issued on December 31, 2010 with a principal amount of $1,197,500 with a maturity date of December 31, 2010.

Promissory Note issued on December 31, 2010 with a principal amount of $409,379 with a maturity date of April 01, 2012.

For the six months ended June 30, 2011 and June 30, 2010 we incurred $725,216 and $561,284, respectively, in interest expense payable to related parties.

NOTE 13: STOCKHOLDERS’ EQUITY (DEFICIT)

EMPLOYEE EQUITY INCENTIVE PLANS

Stock Option Plan

Description of 1998 Stock Incentive Plan

In 1998, the Company’s Board of Directors and shareholders approved the 1998 Stock Incentive Plan of OmniComm Systems, Inc. (the “1998 Plan”). The 1998 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 1998 Plan, 12,500,000 shares of the Company’s common stock were authorized for issuance. The 1998 Plan expired as of December 31, 2008. As of June 30, 2011, there were 6,877,000 outstanding options granted under the 1998 Plan.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

Description of 2009 Equity Incentive Plan

In 2009, the Company’s Board of Directors and shareholders approved the 2009 Equity Incentive Plan of OmniComm Systems, Inc. (the “2009 Plan”). The 2009 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 2009 Plan, 7,500,000 shares of the Company’s common stock are authorized for issuance.

The maximum term for any option grant under the 2009 Plan is ten years from the date of the grant; however, options granted under the 2009 Plan will generally expire five years from the date of grant for most employees, officers and directors of the Company. Options granted to employees generally vest either upon grant or in two installments with the first installment vesting 50% upon completion of one full year from date of grant and on the next anniversary of the employee’s employment. The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees.

As of June 30, 2011, there were 5,862,500 outstanding options that had been granted under the 2009 Plan. At June 30, 2011, there were 1,637,500 shares available for grant as options or other forms of share-based compensation under the 2009 Plan. As of June 30, 2011, substantially all of the Company’s employees were participating in either the 1998 Plan or 2009 Plan.

The following table summarizes the stock option activity for the Company’s equity incentive plans:

	Number of Shares			Weighted Average Exercise Price (per share)			Weighted Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value in (000's)

Outstanding at December 31, 2008		10,997,770		$	0.46
Granted		2,890,000			0.22
Exercised		-0-			-0-
Forfeited/Cancelled/Expired		(1,826,270	)		(0.43	)

Outstanding at December 31, 2009		12,061,500			0.40			3.62	$	-0-
Granted		1,865,000			0.23
Exercised		-0-			-0-
Forfeited/Cancelled/Expired		(2,104,500	)		(0.32	)

Outstanding at December 31, 2010		11,822,000			0.39			3.21	$	-0-
Granted		1,402,500			0.13
Exercised		-0-			-0-
Forfeited/Cancelled/Expired		(485,000	)		0.30

Outstanding at June 30, 2011		12,739,500		$	0.36			3.00	$	-0-


Vested and Exercisable at June 30, 2011		10,924,500		$	0.40			2.74	$	-0-

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price at fiscal year-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2011.

The total number of shares vested and the fair value of shares vested for the six months ended June 30, 2011 and June 30, 2010, respectively, was:

	Number of Options Vested		Fair Value of Options Vested
Fair value of options vested during the six months ended June 30, 2011		1,165,000	$	292,453

Fair value of options vested during the six months ended June 30, 2010		1,715,000	$	353,875

Cash received from stock option exercises for the six months ended June 30, 2011 and June 30, 2010 was $-0- and $-0-, respectively. Due to the Company’s net loss position, no income tax benefit has been realized during the six months ended June 30, 2011 and June 30, 2010.

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The following table summarizes information concerning options outstanding at June 30, 2011:

Awards Breakdown by Range as at June 30, 2011
	Outstanding						Vested
Strike Price Range	Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Outstanding Strike Price		Vested		Weighted Average Remaining Vested Contractual Life		Weighted Average Vested Strike Price
0 to 0.20		3,187,500		4.13	$	0.16		1,400,000		3.51	$	0.20
0.21 to 0.29		4,320,000		2.85	$	0.26		4,292,500		2.85	$	0.26
0.30 to 0.49		880,000		2.41	$	0.45		880,000		2.41	$	0.45
0.50 to 0.70		4,352,000		2.45	$	0.60		4,352,000		2.45	$	0.60
0 to 0.70		12,739,500		3.00	$	0.36		10,924,500		2.74	$	0.40

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The following table summarizes information concerning options outstanding at June 30, 2010:

Awards Breakdown by Range as at June 30, 2010
	Outstanding						Vested
Range	Outstanding		WA Remaining Contractual Life		WA Outstanding Strike Price		Vested		Remaining Vested Contractual Life		WA Vested Strike Price
0 to 0.20		1,790,000		4.50	$	0.20		1,330,000		4.51	$	0.20
0.21 to 0.29		5,545,000		3.24	$	0.26		4,536,666		3.00	$	0.26
0.30 to 0.49		1,250,000		3.68	$	0.45		1,210,000		3.70	$	0.45
0.50 to 0.70		4,686,500		3.46	$	0.60		3,980,250		3.58	$	0.60
0 to 0.70		13,271,500		3.53	$	0.39		11,056,916		3.47	$	0.40

Basis for Fair Value Estimate of Share-Based Payments

Based on analysis of its historical volatility, the Company expects that the future volatility of its share price is likely to be similar to the historical volatility the Company experienced since the Company’s commercialization activities were initiated during the second half of 2000. The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments granted during fiscal 2011 and 2010. Actual volatility, and future changes in estimated volatility, may differ substantially from the Company’s current estimates.

The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The table below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted.

The fair value of share-based payments was estimated using the American Binomial option pricing model with the following assumptions for grants made during the periods indicated.

	Stock Option Assumptions for the six months ended
	June 30, 2011			June 30, 2010
Stock Option Assumptions
Risk-free interest rate		2.24	%		2.43	%
Expected dividend yield		0.0	%		0.00	%
Expected volatility		126.1	%		72.5	%
Expected life of options (in years)		5.0			5.0

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

The following table summarizes weighted average grant date fair value activity for the Company incentive stock plans:

	Weighted Average Grant-Date Fair Value
	2011		2010
Stock options granted during the three month period ended June 30,	$	0.13	$	0.10

Stock options vested during the three month period ended June 30,	$	0.25	$	0.21

Stock options forfeited during the three month period ended June 30,	$	0.30	$	0.19

A summary of the status of the Company’s nonvested shares underlying stock options as of June 30, 2011, and changes during the six months ended June 30, 2011 is as follows:

	Shares Underlying Stock Options		Weighted Average Grant Date Fair Value
Nonvested Shares at January 1, 2011		1,610,000	$	0.36

Nonvested Shares at June 30, 2011		1,815,000	$	0.25

As of June 30, 2011, approximately $153,766 of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of 2.36 years.

Warrants Issued for Services and in Capital Transactions

The following tables summarize all warrants issued to consultants and warrants issued as part of convertible debt transactions for the six months ended June 30, 2011 and June 30, 2010, and the related changes during these periods are presented below.

June 30, 2011 Warrants Outstanding									June 30, 2011 Warrants Exercisable
	Range of Exercise Price		Number Outstanding at		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable at		Weighted Average Exercise Price
			June 30, 2011						June 30, 2011
	$	0.25 – 0.60		52,195,758		2.19	$	0.40		52,195,758	$	0.40

June 30, 2010 Warrants Outstanding									June 30, 2010 Warrants Exercisable
	Range of Exercise Price		Number Outstanding at		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable at		Weighted Average Exercise Price
			June 30, 2010						June 30, 2010
	$	0.25 – 0.60		40,808,241		2.47	$	0.44		40,808,241	$	0.44

Warrants
Balance at June 30, 2010		40,808,241
Issued		-0-
Exercised		-0-
Forfeited		-0-
Balance at December 31, 2010		40,808,241
Issued		11,467,517
Exercised		-0-
Forfeited		(80,000	)
Balance at June 30, 2011		52,195,758
Warrants Exercisable at June 30, 2011		52,195,758
Weighted Average Fair Value of Warrants Granted During 2011	$	0.25

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2011

Other Comprehensive Gain (Loss)

Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive gain (loss). The following table lists the beginning balance, yearly activity and ending balance of the components of accumulated other comprehensive gain (loss).

	Foreign Currency Translation			Accumulated Other Comprehensive Gain (Loss)
Balance December 31, 2009	$	2,934		$	2,934

2010 Activity		(27,232	)		(27,232	)

Balance December 31, 2010		(24,298	)		(24,298	)

2011 Activity		(11,514	)		(11,514	)
Balance at June 30, 2011	$	(35,812	)	$	(35,812	)

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the information contained in our unaudited consolidated financial statements and notes thereto appearing elsewhere herein and other information set forth in this report. Reference to “us” “we” “our” the “Company” means OmniComm Systems, Inc.®. and our wholly owned subsidiaries OmniComm USA, Inc., OmniComm Ltd., and OmniComm Europe GmbH.

Forward-Looking Statements

Statements contained in this quarterly report on Form 10-Q that are not historical fact are "forward looking statements". These statements can often be identified by the use of forward-looking terminology such as "estimate", "project", "believe", "expect", "may", "will", "should", "intends", or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, contained in this quarterly report on Form 10-Q regarding matters that are not historical facts, are only predictions. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this quarterly report on Form 10-Q. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward- looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. The Company does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

Overview

We are a healthcare technology company that provides Web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations, and other clinical trial sponsors worldwide. Our proprietary EDC software applications: TrialMaster®; TrialOne®; and eClinical Suite™ (the “eClinical Software Products”), allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data.

During the first six months of fiscal 2011 we sought to build and expand on our strategic efforts. The primary focus of our strategy includes:

Stimulating demand by providing clinical trial sponsors with high value eClinical applications and services;

Emphasizing low operating costs;

Continued emphasis on expanding our business model by offering our software solutions on a licensed basis in addition to our existing hosted-services solutions;

Broadening our eClinical suite of services and software applications on an organic R & D basis and on a selective basis via the acquisition or licensing of complementary solutions;

An emphasis on penetrating the Phase I trial market with our dedicated Phase I solution, TrialOne;

Expanding our business development efforts in Europe to capitalize on our operational and clinical capabilities vis-à-vis our competition in that geographic market;

Providing our services to small and midsize pharmaceutical, biotechnology, medical device companies and CROs; and

Expanding our penetration of the large pharmaceutical sponsor market by leveraging the client contracts we assumed from our 2009 acquisitions.

Our operating focus is first, to increase our sales and marketing capabilities and penetration rate and secondly, to continue developing and improving our software solutions and services to ensure our services and products remain an attractive, high-value EDC choice. During the first six months of 2011, we increased our marketing and sales personnel both in the U.S. and European markets. We continue to seek new opportunities in our CRO Preferred Program in order to increase our penetration of the domestic CRO market. The CRO Preferred Program offers fixed pricing and pay-as-you-go hosted services. Additionally, we believe we have established an effective presence in the European clinical trial market by expanding the number of clients we service in the European market after the acquisition of the EDC assets of eResearch Technology, Inc., (“eRT” or “eResearch Technologies”). We will seek to continue to aggressively expand the scope of our sales and marketing operations in Europe during the remainder of fiscal 2011.

Our ability to compete within the EDC and eClinical industries is predicated on our ability to continue enhancing and broadening the scope of solutions we offer. Our R & D efforts are focused on developing new, complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. We spent approximately $1,286,630 and $1,844,866 on R & D activities during six months ended June 30, 2011 and June 30, 2010, respectively. The decrease in R & D expenditure is due in large part to a migration of a portion of our R & D employees to Cost of Goods sold and other departments as our core product matures. The majority of our R & D expenses represent salaries to our developers. In addition, we decreased our overall R & D personnel by about 20% during fiscal 2010 in an effort to more closely align our cost structure with expected revenues.

Our selling efforts include marketing our products to several Fortune 1000 pharmaceutical and medical device manufacturers and several of the largest CROs. We have experienced, both via organic growth and through our 2009 acquisitions, success in broadening our client roster over the past several fiscal years. Continued success in broadening our existing client relationships and forging new relationships should provide us the opportunity to limit our need for funding our operations via debt and equity capital. Continuing to obtain contracts with clients of this size and reputation will also increase the credibility of the Company to the clinical trial market.

Our business development focus continues to include increasing our penetration of all phases of the clinical trial market with a continued emphasis on becoming the market leader in Phase I EDC services. We believe this market is an operating and strategic strength of the Company due to the inherent flexibility of our solutions including the solutions provided by our TrialOne products and services. We believe we have the ability to produce trials more quickly and economically than our competitors for this specialized and large market. During the first six months of fiscal 2011, we emphasized commercializing our products on a licensed basis. During 2010 we experienced mixed results in achieving this goal. We were able to increase the scope of licenses existing clients had deployed in our eClinical Suite and TrialMaster product lines. We found that the sale of licenses of our eClinical Software Products to new clients was somewhat hampered by what we perceived as a sluggish market for R & D spending. We expect to experience increased success in penetrating the market for larger pharmaceutical, biotechnology and medical device clinical trial sponsors as we continue expanding our marketing and sales efforts during the remainder of fiscal 2011.

Our clients are able to partially or completely license our EDC solutions. The licensing business model provides our clients a more cost effective means of deploying our EDC solutions on a large-scale basis. Our licensed products, falling under the auspices of either a Tech Transition (partial transfer with some services performed by OmniComm) or Tech Transfer, allow us to broaden our potential client base, provide us with a high-margin revenue source and affords us the ability to improve our competitive position within the EDC industry. The acquisitions completed during fiscal 2009 (the eResearch EDC Assets and TrialOne) have historically been sold on a licensed basis and have allowed us to broaden our base of licensed customers. Additionally, we continue to focus on adding CROs as strategic and marketing partners. There is an industry-wide emphasis in establishing strategic relationships with CROs. These relationships provide marketing leverage in the form of joint marketing and sales efforts and provide an installed base of trained users for our EDC and eClinical Suite software applications. This installed base of users increases our ability to provide rapidly developed, cost effective solutions for our clients. Additionally, we believe we have established an effective presence in the European clinical trial market and will seek to aggressively expand the scope of our sales and marketing operations there. The European market accounts for approximately 21% and 13% of total revenues for the six months ended June 30, 2011 and June 30, 2010, respectively.

We feel that the momentum established from new client acquisitions and our ability to retain clients for repeat engagements provide a good operating base from which to build during fiscal 2011. We have increased the marketing and business development budget for our TrialOne product during 2011 as we have placed increased emphasis on increasing our penetration of the Phase I market both in the U.S. and in Europe since we believe that segment of the EDC market is the least penetrated and allows for the greatest potential increases in market share and in sales volumes. We expect to continue increasing the level of resources deployed in our sales and marketing efforts. We feel that a combination of our existing infrastructure, broadened array of eClinical products and services, and increased success in new client acquisition, coupled with our ability to retain our existing clients will allow us to compete effectively within the EDC market.

The six months-ended June 30, 2011 compared with the six months ended June 30, 2010

Results of Operations

A summarized version of our results of operations for the six months ended June 30, 2011 and June 30, 2010 is included in the table below.

	Summarized Statement of Operations
	For the six months ended
	June 30,
				% of						% of			$			%
	2011			Revenues			2010			Revenues			Change			Change
Total revenues	$	6,666,187					$	5,907,352					$	758,835			12.8	%

Cost of sales		943,972			14.2	%		813,403			13.8	%		130,569			16.1	%

Gross margin		5,722,215			85.8	%		5,093,949			86.2	%		628,266			12.3	%

Salaries, benefits and related taxes		4,188,364			62.8	%		5,421,648			91.8	%		(1,233,284	)		-22.7	%
Rent		451,017			6.8	%		434,809			7.4	%		16,208			3.7	%
Consulting		152,855			2.3	%		292,377			4.9	%		(139,522	)		-47.7	%
Legal and professional fees		240,795			3.6	%		184,065			3.1	%		56,730			30.8	%
Other expenses		837,264			12.6	%		883,675			15.0	%		(46,411	)		-5.3	%
Selling, general and administrative		514,724			7.7	%		709,073			12.0	%		(194,349	)		-27.4	%
Total operating expenses		6,385,019			95.8	%		7,925,647			134.2	%		(1,540,628	)		-19.4	%

Operating loss		(662,804	)		-9.9	%		(2,831,698	)		-47.9	%		2,168,894			-76.6	%

Interest expense		(1,273,221	)		-19.1	%		(1,956,101	)		-33.1	%		682,880			-34.9	%
Interest income		4,625			0.1	%		48			0.0	%		4,577			9534.8	%
Other Comprehensive Income (Loss)		4,915			0.1	%		-0-			0.0	%		4,915			0.0	%
Change in derivatives		(2,964,751	)		-44.5	%		3,483,649			59.0	%		(6,448,400	)		-185.1	%

Net loss		(4,891,236	)		-73.4	%		(1,304,102	)		-22.1	%		(3,587,134	)		275.1	%

Preferred stock dividends					0.0	%					0.0	%
Total preferred stock dividends		(102,004	)		-1.5	%		(102,004	)		-1.7	%		-			0.0	%

Net loss attributable to common stockholders	$	(4,993,240	)		-74.9	%	$	(1,406,106	)		-23.8	%	$	(3,587,134	)		255.1	%

Net loss per share	$	(0.06	)				$	(0.02	)

Weighted average number of shares outstanding		86,207,462						85,507,699

Revenues for the six months ended June 30, 2011 increased approximately 12.8% or $758,835 from the six months ended June 30, 2010. The table below provides a comparison of our recognized revenues for the six months ended June 30, 2011 and June 30, 2010.

	For the six months ended
Business Activity	June 30, 2011				June 30, 2010				Increase $			Increase %
Set-up Fees	$	1,586,262	23.8	%	$	2,115,769	35.8	%	$	(529,507	)		-25.0	%
Change Orders		160,902	2.4	%		81,546	1.4	%		79,356			97.3	%
Maintenance		2,764,632	41.5	%		2,149,614	36.4	%		615,018			28.6	%
Software Licenses		1,617,406	24.3	%		742,202	12.6	%		875,204			117.9	%
Professional Services		242,703	3.6	%		456,499	7.7	%		(213,796	)		-46.8	%
Hosting		294,282	4.4	%		361,722	6.1	%		(67,440	)		-18.6	%
Totals	$	6,666,187	100.0	%	$	5,907,352	100.0	%	$	758,835			12.8	%

Revenues from our TrialMaster ASP fees and maintenance from existing TrialMaster clients increased by $354,100 or 13.1% for the six months ended June 30, 2011 when compared to the six month period ended June 30, 2010. During 2009 and 2010 our primary customer base which consisted primarily of small, U.S.-based biotechnology firms, dramatically reduced the level of clinical trials they were conducting. Many of these firms are pre-revenue and as we understand are reliant on the capital markets for working capital and R & D funding. With the difficult economic climate experienced beginning in late 2008 and continuing through the end of fiscal 2010 we believe that many of these firms either reduced or completely curtailed their R & D activities either because of a lack of capital or in order to conserve their cash reserves. We have seen evidence since late 2009 of increased activity from these clients but have not seen a complete recovery of this market segment’s R & D spending. In addition, we have placed an emphasis on increasing the number of customers licensing the TrialMaster software suite. The licensing business model allows for more regular revenue recognition and operating cash flows, greater visibility into our operating results and has the potential, in the long-run, for stronger gross margins since the manpower requirements are smaller than under an ASP model thus producing less cost of goods sold.

We recorded $701,351 in revenues from our licensing activity and $67,561 from professional services associated with our TrialMaster suite during the six months ended June 30, 2011 compared with $305,871 and $111,945, respectively, during the six months ended June 30, 2010.

We expect revenues from both activities to increase during the remainder of fiscal 2011 for several reasons. First, we see significant activity in the CRO market relating to infrastructure investing. Second, we have entered into a contract with Kendle International for them to license our TrialMaster application. Third, as customers increase their use of eClinical solutions they tend to standardize their data collection practices. It is significantly more cost effective to deploy eClinical software on a licensed basis. The ability to undertake this kind of operational change is however predicated on having the network and technical infrastructure needed to replicate most of the services, support and infrastructure we provide on an ASP basis.

We recorded $1,888,135 in revenues associated with clients with our acquisition of the eResearch Technology eClinical Suite software application during the six months ended June 30, 2011 compared with $2,553,068 for the six months ended June 30, 2010, a decrease of $664,933, or 26.0%. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with our hosting and maintenance services. During fiscal 2010 we experienced significant license renewals/additions for this product. Because of the long-term nature of many of these relationships many of the license purchases were one-time purchases aimed at increasing the total number of licenses available for use.

We recorded $294,282 in revenues from hosting and subscriptions activities and $104,311 in consulting services associated with the eClinical Suite during the six months ended June 30, 2011 compared with $361,722 and $344,554, respectively, for the six months ended June 30, 2010. Generally, these revenues are paid monthly and are connected to hosting, maintenance and client support for clients licensing that application.

We recorded $727,177 in revenues associated with clients on our TrialOne EDC software and other Phase I EDC products and services for the six months ended June 30, 2011 compared with $148,307 for the six months ended June 30, 2010. We have begun increasing our efforts at commercializing and developing our sales and marketing campaign for the TrialOne application. We have significantly increased our participation in industry trade shows and conferences and are in the process of developing a dedicated sales force for the TrialOne software. TrialOne revenues are comprised of license subscriptions, maintenance services and professional services since the software is currently only sold under a technology transfer basis. We recorded $521,970 from one client during the six months ended June 30, 2011 or 71.6% of revenues for this product line.

Our TrialMaster EDC application has historically been sold on an ASP basis that provides EDC and other services such as an enterprise management suite which assists our clients in the pharmaceutical, biotechnology and medical device industries in accelerating the completion of clinical trials. During 2009, as discussed earlier, we completed the acquisition of the eResearch EDC Assets and TrialOne . Both software applications have historically been sold on a licensed or technology transfer basis. As we continue developing our software applications and our client relationships mature, we expect some of our clients to deploy TrialMaster on a licensed, rather than ASP hosted basis. We expect both the eResearch EDC Assets and TrialOne applications to continue to be sold primarily on a licensed basis.

TrialMaster contracts for ASP services provide for pricing that is based on both the size and duration of the clinical trial. Size parameters include the number of case report forms used to collect data and the number of sites utilizing TrialMaster. The client will pay a trial setup fee based on the previously mentioned factors at the beginning of our engagements and then pay an on-going maintenance fee for the duration of the clinical trial that provides software, network and site support during the trial.

Generally, ASP contracts will range in duration from one month to several years. ASP Setup fees are generally recognized in accordance with Accounting Standards Codification 605 (“ASC 605”) “Revenue Recognition”, which requires that the revenues be recognized ratably over the life of the contract. ASP maintenance fee revenues are earned and recognized monthly. Costs associated with contract revenues are recognized as incurred.

In late 2008, we began selling our core TrialMaster product on a licensed basis. Beginning in the third fiscal quarter of 2009 we experienced greater success in selling TrialMaster on a licensed basis. The EDC assets acquired from eResearch Technology and TrialOne are primarily sold on a licensed basis. License contracts are typically sold on a subscription basis that takes into account system usage both on a data volume and system user basis. Pricing includes additional charges for consulting services associated with the installation, validation, training and deployment of our eClinical Suite software and solutions. Licensed contracts of the eClinical Suite have historically been sold on a perpetual license basis with hosting and maintenance charges being paid annually. The Company expects any licenses it sells of its software products to be sold in three to five year term licenses.

Our top five customers accounted for approximately 40.8% of our revenues during the six months ended June 30, 2011 and approximately 39.9% of our revenues during the six months ended June 30, 2010. One customer accounted for 19.7% of our revenues during the six months ended June 30, 2011. One customer accounted for 22.0% of our revenues during the six months ended June 30, 2010. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

Cost of goods sold increased approximately 16.1% or $130,569 for the six months ended June 30, 2011 as compared to the six months ended June 30, 2010. Cost of goods sold were approximately 14.2% of revenues for the six months ended June 30, 2011 compared to approximately 13.8% for the six months ended June 30, 2010. Cost of goods sold relates primarily to salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients. Although our experience to-date in licensing and deploying TrialMaster on a technology transfer or licensed basis has been limited, we expect our cost of goods sold related to these types of engagements to approximate 20% of revenues associated with those engagements.

We expect to increase development programming and support labor costs on an absolute basis as our trial revenues increase. We expect our cost of goods sold to remain fairly stable as we continue to expand the number of licenses we deploy and service since we expect cost of sales from licensed engagements to fall in the 15% range as that business model matures. We expect to continue to increase follow-on engagements from existing clients and expect to increase the Phase I and CRO portions of our client base. TrialMaster (V4.0) increased the efficiency of our trial building operations by approximately 20% through the use of additional automated tools, the ability to use our library of pre-existing CRFs and through the use of our “drag and drop” clinical trial building tool. We have begun our business development efforts in commercializing TrialOne. We expect to sell TrialOne primarily on a licensed basis providing further basis to our cost of goods sold estimates. At least initially, we expect the costs to deploy TrialOne to exceed our long-term estimates as we develop and refine our installation, validation, and training procedures.

Overall, total operating expenses decreased approximately 19.4% for the six months ended June 30, 2011 when compared to the six months ended June 30, 2010. Total operating expenses were approximately 95.8% of revenues during the six months ended June 30, 2011 compared to approximately 134.2% of revenues for the six months ended June 30, 2010.

Salaries and related expenses were our biggest operating expense at 65.6% of total operating expenses for the six months ended June 30, 2011 and 68.4% of total operating expenses for the six months ended June 30, 2010. Salaries and related expenses decreased approximately 22.7% for the six months ended June 30, 2011 when compared to the same period that ended June 30, 2010. During the second half of fiscal 2010 we reduced our overall staffing levels by approximately 20% in an effort at matching our staffing levels and total compensation costs more closely with our present and expected revenues and operating activities. The table below provides a summary of the significant components of salary and related expenses by primary cost category.

	For the six months ended
	June 30, 2011		June 30, 2010		Change			% Change
OmniComm Corporate Operations	$	2,660,878	$	3,467,327	$	(806,449	)		-23.3	%
New Jersey Operations Office		537,152		716,784		(179,632	)		-25.1	%
OmniComm Europe, GmbH		524,252		632,350		(108,098	)		-17.1	%
OmniComm Ltd.		375,963		247,507		128,456			51.9	%
Employee Stock Option Expense		90,119		357,680		(267,561	)		-74.8	%

Total Salaries and related expenses	$	4,188,364	$	5,421,648	$	(1,233,284	)		-22.7	%

We currently employ approximately 48 employees out of our Ft. Lauderdale, Florida corporate office, seven employees out of our New Jersey field office, eight out-of-state employees, seven employees out of a wholly-owned subsidiary in the United Kingdom and 14 employees out of a wholly-owned subsidiary in Bonn, Germany. We expect to continue to selectively add experienced sales and marketing personnel over the next six months in an effort to increase our market penetration, particularly as it relates to the largest pharmaceutical, biotechnology and CRO customers and to continue broadening our client base domestically as well as in Europe.

During the six months ended June 30, 2011 and the six months ended June 30, 2010 we incurred $90,119 and $357,684, respectively, in salary expense in connection with ASC 718 Compensation – Stock Compensation, which establishes standards for transactions in which an entity exchanges its equity instruments for employee services. This standard requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Rent and related expenses increased by approximately 3.7% during the six months ended June 30, 2011 when compared to the six months ended June 30, 2010 primarily due to a rate increase on our office in the United Kingdom and in connection with increased rental payments on additional office space at our corporate headquarters. Our primary data site is located at a Cincinnati Bell owned co-location facility in Cincinnati, Ohio. We will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% production system up-time and to provide system redundancy. We lease co-location and disaster recovery space in the Ft. Lauderdale, Florida area. This facility provides us with disaster recovery and business continuity services for our operations. This lease expires in August 2012. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH. That lease expires in December 2011. We entered into a lease for office space in New Jersey in order to integrate our acquisition of the eResearch EDC Assets during fiscal 2009. That office lease expires in February 2013. Our OmniComm Ltd. subsidiary entered into a lease for office space during fiscal 2009. That office lease expires in October 2012. During September 2010 we renewed our home office lease. That lease now extends through September 2016. The table below provides the significant components of our rent related expenses by location, subsidiary or operating activity. Deducted from rent during 2011 was $11,789 in non-cash, straight-line rent expense recorded to give effect to contractual, inflation-based rent increases in our leases.

	June 30, 2011			June 30, 2010		Change			% Change
Corporate Office	$	162,993		$	136,598	$	26,395			19.3	%
Co location and disaster recovery facilities		170,952			190,745	$	(19,793	)		-10.4	%
New Jersey Operations Office		38,641			33,852	$	4,789			14.1	%
OmniComm Europe, GmbH		44,340			43,236	$	1,104			2.6	%
OmniComm Ltd.		45,880			30,378	$	15,502			51.03	%
Straight-line rent expense	$	(11,789	)		0	$	(11,789	)		n/m

Total	$	451,017		$	434,809	$	16,208			3.7	%

Consulting services expense decreased to $155,855 for the six months ended June 30, 2011 compared with $292,377 for the six months ended June 30, 2010, a decrease of $136,522 or 46.7%. Consulting services were comprised of fees paid to consultants for help with developing our computer applications, fees incurred as part of our employee recruiting programs and for services related to our sales and marketing efforts. The Company has decreased its use of outside consultants partly as a result of general cost cutting efforts during fiscal 2010. In addition, we decreased employee recruitment spending by bringing most of those efforts in-house. We have also diminished our use of outside consultants in our R & D efforts in an effort to lower operating costs. The table provided below provides the significant components of the expenses incurred related to consulting services.

For the six months ended
Expense Category	June 30, 2011		June 30, 2010		Change			% Change
Employee Recruitment	$	-0-	$	30,000	$	(30,000	)		-100.0	%
Sales & Marketing		900		110,022		(109,122	)		-99.2	%
Product Development		151,955		152,355		(400	)		-0.3	%

	$	152,855	$	292,377	$	(139,522	)		-47.7	%

Legal and professional fees increased approximately 30.8% or $56,730 for the six months ended June 30, 2011 compared with the six months ended June 30, 2010. Professional fees include fees paid to our auditors for services rendered on a quarterly and annual basis in connection with our SEC filings and fees paid to our attorneys in connection with representation in matters involving litigation and acquisitions or for services rendered to us related to securities and SEC filings and related matters. The increase can be attributed to additional amounts spent on consolidating our information systems on the NetSuite ERP application, additional expense recorded on audit fees that is related to the timing of payments and expense recording and legal fees incurred on general corporate matters offset by a decrease in our spending on financial advisory services. The table below compares the significant components of our legal and professional fees for the six months ended June 30, 2011 and June 30, 2010, respectively.

For the six months ended
Expense Category	June 30, 2011		June 30, 2010		Change			% Change
Financial Advisory	$	-0-	$	63,736	$	(63,736	)		-100.0	%
Audit and Related		85,646		30,484		55,162			181.0	%
Accounting Services		85,019		36,299		48,720			134.2	%
Miscellaneous		16,197		10,238		5,959			58.2	%
General Legal		53,933		43,308		10,625			24.5	%

	$	240,795	$	184,065	$	56,730			30.8	%

Selling, general and administrative expenses (“SGA”) decreased approximately 27.4% for the six months ended June 30, 2011 compared to the six months ended June 30, 2010. During the six months ended June 30, 2011 we recorded $122,144 in license fees associated with our license agreement with DataSci, LLC compared to $125,779 during the six months ended June 30, 2010. We recorded a license fee of $2,629 relating to a license agreement with Logos Holdings, Ltd. relating to certain clients we acquired as part of our acquisition of Logos Technologies, Ltd. in August 2009. In addition, SGA expenses relate primarily to costs incurred in running our offices in Fort Lauderdale, New Jersey, Lymington, England and Bonn, Germany on a day-to-day basis and other costs not directly related to other captioned items in our income statement. SGA include the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. The Company decreased its marketing, sales and advertising expenditures by approximately 1.7% or $2,752 for the six months ended June 30, 2011 compared to the six months ended June 30, 2010. Marketing and advertising expenditures relate primarily to amounts spent on our participation in industry trade shows and conferences. During the remainder of year 2011, we expect the amount spent on general corporate marketing to approximate $125,000 to $200,000 in connection with projects related to our corporate website and in conjunction with marketing activities aimed at increasing industry awareness and as well as on marketing campaigns specific to increasing product penetration of TrialOne.

During the six months ended June 30, 2011 we did not incur bad debt expense compared to $13,954 incurred for bad debt expense during the six months ended June 30, 2010. During 2009 and the beginning of 2010, our existing base of TrialMaster clients, which is primarily comprised of small, U.S.-based biotechnology firms, experienced significant problems in obtaining working capital and R & D funding. During 2009 and the first six months of 2010, seven of our clients either ceased operations or severely curtailed their work with us. Since late 2010 we have seen evidence of increased activity in general and believe that our current allowance for uncollectible accounts accurately reflects any accounts which may prove uncollectible during the remainder of fiscal 2011.

Interest expense was $1,273,221 during the six months ended June 30, 2011 compared to $1,956,101 for the six months ended June 30, 2010, a decrease of $682,880. The decrease is partially due to a decrease in the amounts accreted on the discounts recorded on convertible notes originally issued in December 2008 which was offset by interest expense incurred on promissory notes that were issued during fiscal 2010. Interest incurred to related parties was $725,216 during the six months ended June 30, 2011 and $561,284 for the six months ended June 30, 2010, an increase of $163,932 or 29.2%. This increase is primarily related to the issuance of $2,866,879 in promissory notes to our Chief Executive Officer and Director, Cornelis F. Wit during fiscal 2011. The table below provides detail on the significant components of interest expense for the six months ended June 30, 2011 and June 30, 2010.

For the six months ended
Debt Description	June 30, 2011		June 30, 2010		Change $

Accretion of Discount from Derivatives	$	497,884	$	1,342,953	$	(845,069	)
August 2008 Convertible Notes		95,211		112,567		(17,356	)
December 2008 Convertible Notes		296,344		301,997		(5,653	)
Sept 2009 Secured Convertible Debentures		77,260		83,311		(6,051	)
Dec 2009 Convertible Debentures		88,666		88,666		-
General Interest		35,343		14,843		20,500
Related Party Notes		182,514		11,764		170,750
Total	$	1,273,222	$	1,956,101	$	(682,879	)

We evaluate the cost of capital available to us in combination with our overall capital structure and the prevailing market conditions in deciding what financing best fulfills our short and long-term capital needs. Given the difficult overall economic climate and in particular the difficulties nano-cap companies have experienced in obtaining financing, we believe the structure and terms of the transactions we entered into from 2008 to 2010, and during the first six months of 2011 were obtained at the best terms available to the Company.

We recorded unrealized losses related to changes in our derivative liabilities associated with the issuance of convertible notes that occurred from fiscal 2008 to 2010. We recorded a net unrealized loss of $2,964,751 during the six months ended June 30, 2011 compared with a net unrealized gain of $3,483,649 during the six months ended June 30, 2010. The unrealized gains and losses can be attributed to fair value calculations undertaken periodically on the warrant and conversion feature liabilities recorded by us at the time the convertible notes were issued. Accordingly, the warrant and conversion feature liabilities are increased or decreased based on the fair value calculations made at each balance sheet date. During the six month ended June 30, 2011, several factors combined to produce the significant unrealized loss from derivative changes we recorded. These factors include: 1) a significant increase in the share price on the OTC Bulletin Board of our common stock; 2) a marked increase in the calculated volatility used in the valuation model used in determining the fair value of our derivative liabilities; and 3) the maturity date of two rounds of outstanding convertible notes was extended by two years. This extension increased the fair value of the conversion feature liability underlying the convertible notes. These non-cash gains and losses have materially impacted our results of operations during the six months ended June 30, 2011 and during fiscal years 2010, 2009, and 2008 and can be reasonably anticipated to materially affect our net loss or net income in future periods. We are, however, unable to estimate the amount of such income/expense in future periods as the income/expense is partly based on the market price of our common stock at the end of a future measurement date. In addition, in the future if we issue securities which are classified as derivatives we will incur expense and income items in future periods. Investors are cautioned to consider the impact of this non-cash accounting treatment on our financial statements.

The Company recorded arrearages of $102,004 in its 5% Series A Preferred Stock dividends for the six months ended June 30, 2011 and June 30, 2010. As of June 30, 2011, the Company had cumulative arrearages for preferred stock dividends as follows:

Series of Preferred Stock	Cumulative Arrearage

Series A	$	1,790,894
Series B		609,904
Series C		1,469,593
Total Preferred Stock Arrearages	$	3,870,391

The three months-ended June 30, 2011 compared with the three months ended June 30, 2010

Results of Operations

A summarized version of our results of operations for the three months ended June 30, 2011 and June 30, 2010 is included in the table below.

	Summarized Statement of Operations
	For the three months ended
	June 30,
				% of						% of			$				%
	2011			Revenues			2010			Revenues			Change			Change
Total revenues	$	3,351,520					$	3,209,989					$	141,531			4.4	%

Cost of sales		497,917			14.9	%		378,532			11.8	%		119,385			31.5	%

Gross margin		2,853,603			85.1	%		2,831,457			88.2	%		22,146			0.8	%

Salaries, benefits and related taxes		2,089,623			62.3	%		2,735,898			85.2	%		(646,275	)		-23.6	%
Rent		225,980			6.7	%		234,074			7.3	%		(8,094	)		-3.5	%
Consulting		102,676			3.1	%		81,652			2.5	%		21,024			25.7	%
Legal and professional fees		104,665			3.1	%		98,549			3.1	%		6,116			6.2	%
Other expenses		407,225			12.2	%		419,277			13.1	%		(12,052	)		-2.9	%
Selling, general and administrative		228,758			6.8	%		468,056			14.6	%		(239,298	)		-51.1	%
Total operating expenses		3,158,927			94.3	%		4,037,506			125.8	%		(878,579	)		-21.8	%

Operating loss		(305,324	)		-9.1	%		(1,206,049	)		-37.6	%		900,725			-74.7	%

Interest expense		(642,617	)		-19.2	%		(985,593	)		-30.7	%		342,976			-34.8	%
Interest income		4,236			0.1	%		1			0.0	%		4,235			423527.0	%
Gain (Loss) on extinguishment of debt		-0-			0.0	%		-0-			0.0	%		-0-			0.0	%
Other Comprehensive Income (Loss)		574			0.0	%		-0-			0.0	%		574			0.0	%
Change in derivatives		(54,181	)		-1.6	%		2,407,655			75.0	%		(2,461,836	)		-102.3	%

Net loss		(997,312	)		-29.8	%		216,014			6.7	%		(1,213,326	)		-561.7	%
Total preferred stock dividends		(51,284	)		-1.5	%		(51,284	)		-1.6	%		-			0.0	%

Net loss attributable to common stockholders	$	(1,048,596	)		-31.3	%	$	164,730			5.1	%	$	(1,213,326	)		-736.6	%

Net loss per share	$	(0.01	)				$	0.00

Weighted average number of shares outstanding		86,332,044						85,507,699

Revenues for the three months ended June 30, 2011 increased approximately 4.4% or $141,531 for the three months ended June 30, 2010. The table below provides a comparison of our recognized revenues for the three months ended June 30, 2011 and June 30, 2010.

	For the three months ended
Business Activity	June 30, 2011				June 30, 2010				Increase $			Increase %
Set-up Fees	$	830,708	24.8	%	$	1,218,276	38.0	%	$	(387,568	)		-31.8	%
Change Orders		83,022	2.5	%		53,586	1.7	%		29,436			54.9	%
Maintenance		1,331,152	39.7	%		1,086,779	33.9	%		244,373			22.5	%
Software Licenses		798,352	23.8	%		405,887	12.6	%		392,465			96.7	%
Professional Services		145,696	4.3	%		231,183	7.2	%		(85,487	)		-37.0	%
Hosting		162,590	4.9	%		214,278	6.7	%		(51,688	)		-24.1	%
Totals	$	3,351,520	100.0	%	$	3,209,989	100.0	%	$	141,531			4.4	%

Revenues from our TrialMaster ASP fees and maintenance from existing TrialMaster clients increased by $15,755 or 1.0% for the three months ended June 30, 2011 when compared to the three month period ended June 30, 2010. During 2009 and 2010 our primary customer base which consisted primarily of small, U.S.-based biotechnology firms, dramatically reduced the level of clinical trials they were conducting. Many of these firms are pre-revenue and as we understand are reliant on the capital markets for working capital and R & D funding. With the difficult economic climate experienced beginning in late 2008 and continuing through the end of fiscal 2010 we believe that many of these firms either reduced or completely curtailed their R & D activities either because of a lack of capital or in order to conserve their cash reserves. We have seen evidence since late 2009of increased activity from these clients but have not seen a complete recovery of this market segment’s R & D spending. In addition, we have placed an emphasis on increasing the number of customers licensing the TrialMaster software suite. The licensing business model allows for more regular revenue recognition and operating cash flows, greater visibility into our operating results and has the potential, in the long-run, for stronger gross margins since the manpower requirements are smaller than under an ASP model thus producing less cost of goods sold.

We recorded $480,056 in revenues from our licensing activity and $43,565 from professional services associated with our TrialMaster suite during the three months ended June 30, 2011 compared with $173,202 and $76,145, respectively, during the three months ended June 30, 2010.

We recorded $972,502 in revenues associated with clients with our acquisition of the eResearch Technology eClinical Suite software application (“eClinical”) during the three months ended June 30, 2011 compared with $1,299,000 for the three months ended June 30, 2010, a decrease of $326,498 or 25.1%. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with our hosting and maintenance services. During fiscal 2010 we experienced significant license renewals/additions for this product. Because of the long-term nature of many of these relationships many of the license purchases were one-time purchases aimed at increasing the total number of licenses available for use.

We recorded $165,172 in revenues associated with clients on our TrialOne EDC software and other Phase I EDC products and services for the three months ended June 30, 2011 compared with $76,954 for the three months ended June 30, 2010. We have begun increasing our efforts at commercializing and developing our sales and marketing campaign for the TrialOne application. We have significantly increased our participation in industry trade shows and conferences and are in the process of developing a dedicated sales force for the TrialOne software. TrialOne revenues are comprised of license subscriptions, maintenance services and professional services since the software is currently only sold under a technology transfer basis.

Our TrialMaster EDC application has historically been sold on an application ASP basis that provides EDC and other services such as an enterprise management suite which assists our clients in the pharmaceutical, biotechnology and medical device industries in accelerating the completion of clinical trials. During 2009, as discussed earlier, we completed the acquisition of the eResearch EDC Assets and TrialOne. Both software applications have historically been sold on a licensed or technology transfer basis. As we continue developing our software applications and our client relationships mature, we expect some of our clients to deploy TrialMaster on a licensed, rather than ASP hosted basis. We expect both the eResearch EDC Assets and TrialOne applications to continue to be sold primarily on a licensed basis.

In late 2008, we began selling our core TrialMaster product on a licensed basis. Beginning in the third fiscal three quarter of 2009 we have experienced greater success in selling TrialMaster on a licensed basis. The EDC assets acquired from eResearch Technology and TrialOne are primarily sold on a licensed basis. License contracts are typically sold on a subscription basis that takes into account system usage both on a data volume and system user basis. Pricing includes additional charges for consulting services associated with the installation, validation, training and deployment of our eClinical Suite software and solutions. Licensed contracts of the eClinical Suite have historically been sold on a perpetual license basis with hosting and maintenance charges being paid annually. The Company expects any licenses it sells of its software products to be sold in three to five year term licenses.

Our top five customers accounted for approximately 41.9% of our revenues during the three months ended June 30, 2011 and approximately 43.4% of our revenues during the three months ended June 30, 2010. One customer accounted for 22.4% of our revenues during the three months ended June 30, 2011. One customer accounted for 24.1% of our revenues during the three months ended June 30, 2010. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

Cost of goods sold increased approximately 31.5% or $119,385 for the three months ended June 30, 2011 as compared to the three months ended June 30, 2010. Cost of goods sold were approximately 14.9% of revenues for the three months ended June 30, 2011 compared to approximately 11.8% for the three months ended June 30, 2010. Cost of goods sold relates primarily to salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients. Although our experience to-date in licensing and deploying TrialMaster on a technology transfer or licensed basis has been limited, we expect our cost of goods sold related to these types of engagements to approximate 20% of revenues associated with those engagements.

Overall, total operating expenses decreased approximately 21.8% for the three months ended June 30, 2011 when compared to the three months ended June 30, 2010. Total operating expenses were approximately 94.3% of revenues during the three months ended June 30, 2011 compared to approximately 125.8% of revenues for the three months ended June 30, 2010.

Salaries and related expenses were our biggest operating expense at 66.1% of total operating expenses for the three months ended June 30, 2011 and 67.8% of total operating expenses for the three months ended June 30, 2010. Salaries and related expenses decreased approximately 23.6% for the three months ended June 30, 2011 when compared to the same period that ended June 30, 2010. During the second half of fiscal 2010 we reduced our overall staffing levels by approximately 20% in an effort at matching our staffing levels and total compensation costs more closely with our present and expected revenues and operating activities. The table below provides a summary of the significant components of salary and related expenses by primary cost category.

	For the three months ended
	June 30, 2011		June 30, 2010		Change			% Change
OmniComm Corporate Operations	$	1,322,299	$	1,735,944	$	(413,645	)		-23.8	%
New Jersey Operations Office	$	257,410		353,842		(96,432	)		-27.3	%
OmniComm Europe, GmbH	$	267,841		295,849		(28,008	)		-9.5	%
OmniComm Ltd.	$	212,290		122,366		89,924			73.5	%
Employee Stock Option Expense	$	29,783		227,897		(198,114	)		-86.9	%

Total Salaries and related expenses	$	2,089,623	$	2,735,898	$	(646,275	)		-23.6	%

During the three months ended June 30, 2011 and the three months ended June 30, 2010 we incurred $29,783 and $227,897, respectively, in salary expense in connection with ASC 718 Compensation – Stock Compensation, which establishes standards for transactions in which an entity exchanges its equity instruments for employee services. This standard requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Rent and related expenses decreased by approximately 3.5% during the three months ended June 30, 2011 when compared to the three months ended June 30, 2010 primarily due to a rate increase on our office in the United Kingdom and in connection with increased rental payments on additional office space at our corporate headquarters. Our primary data site is located at a Cincinnati Bell owned Co-Location facility in Cincinnati, Ohio. We will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% production system up-time and to provide system redundancy. We lease co-location and disaster recovery space in the Ft. Lauderdale, Florida area. This facility provides us with disaster recovery and business continuity services for our operations. This lease expires in August 2012. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH. That lease expires in December 2011. We entered into a lease for office space in New Jersey in order to integrate our acquisition of the eResearch EDC Assets during the third three months of fiscal 2009. That office lease expires in February 2013. Our OmniComm Ltd. subsidiary entered into a lease for office space during the fourth three months of 2009. That office lease expires in October 2012. During September 2010 we renewed our home office lease. That lease now extends through September 2016. The table below provides the significant components of our rent related expenses by location, subsidiary or operating activity. Deducted from rent during 2011 was $3,180 in non-cash, straight-line rent expense recorded to give effect to contractual, inflation-based rent increases in our leases.

For the three months ended
	June 30, 2011			June 30, 2010		Change			% Change
Corporate Office	$	82,082		$	83,164	$	(1,082	)		-1.3	%
Co location and disaster recovery facilities		81,549			94,596		(13,047	)		-13.8	%
New Jersey Operations Office		19,482			18,301		1,181			6.5	%
OmniComm Europe, GmbH		22,344			20,817		1,527			7.3	%
OmniComm Ltd.		23,703			17,196		6,507			37.8	%
Straight-line rent expense		(3,180	)		0		(3,180	)		n/m

Total	$	225,980		$	234,074	$	(8,094	)		-3.5	%

Consulting services expense increased to $102,676 for the three months ended June 30, 2011 compared with $81,652 for the three months ended June 30, 2010, an increase of $21,024 or 25.7%. Consulting services were comprised of fees paid to consultants for help with developing our computer applications, fees incurred as part of our employee recruiting programs and for services related to our sales and marketing efforts. The Company has increased its use of outside consultants in an effort to augment our in-house R & D efforts. The consulting engagements that have been undertaken or that are currently contemplated for the balance of 2011 involve development projects either non-core functionality of our software applications or are for highly specialized work that do not warrant the addition of full-time staff due to their non-recurring nature. In addition, we decreased employee recruitment spending by bringing most of those efforts in-house. The table provided below provides the significant components of the expenses incurred related to consulting services.

For the three months ended
Expense Category	June 30, 2011		June 30, 2010			Change		% Change
Employee Recruitment	$	-0-	$	-0-		$	-0-		0.0	%
Sales & Marketing		-0-		(15,750	)		15,750		n/m
Product Development		102,676		97,402			5,274		5.4	%

	$	102,676	$	81,652		$	21,024		25.7	%

Legal and professional fees increased approximately 6.2% or $6,116 for the three months ended June 30, 2011 compared with the three months ended June 30, 2010. Professional fees include fees paid to our auditors for services rendered on a monthly and annual basis in connection with our SEC filings and fees paid to our attorneys in connection with representation in matters involving litigation and acquisitions or for services rendered to us related to securities and SEC filings and related matters. The increase can be attributed to additional amounts spent on consolidating our information systems on the NetSuite ERP application, additional expense recorded on audit fees that is related to the timing of payments and expense recording and legal fees incurred on general corporate matters offset by a decrease in our spending on financial advisory services. The table below compares the significant components of our legal and professional fees for the three months ended June 30, 2011 and June 30, 2010, respectively.

For the three months ended
Expense Category	June 30, 2011		June 30, 2010		Change			% Change
Financial Advisory	$	-0-	$	25,779	$	(25,779	)		-100.0	%
Audit and Related		43,641		22,652		20,989			92.7	%
Accounting Services		35,798		15,936		19,862			124.6	%
Miscellaneous		8,087		7,055		1,032			14.6	%
General Legal		17,139		27,127		(9,988	)		-36.8	%

	$	104,665	$	98,549	$	6,116			6.2	%

Selling, general and administrative expenses (“SGA”) decreased approximately 51.1% for the three months ended June 30, 2011 compared to the three months ended June 30, 2010. During the three months ended June 30, 2011 we recorded $61,975 in license fees associated with our license agreement with DataSci, LLC compared to $84,507 during the three months ended June 30, 2010. We recorded a license fee of $2,693 relating to a license agreement with Logos Holdings, Ltd. relating to certain clients we acquired as part of our acquisition of Logos Technologies, Ltd. in August 2009. In addition, SGA expenses relate primarily to costs incurred in running our offices in Fort Lauderdale, New Jersey, Lymington, England and Bonn, Germany on a day-to-day basis and other costs not directly related to other captioned items in our income statement. SGA include the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. The Company decreased its marketing, sales and advertising expenditures by approximately 19.3% or $18,465 for the three months ended June 30, 2011 compared to the three months ended June 30, 2010.

Interest expense was $642,617 during the three months ended June 30, 2011 compared to $985,593 for the three months ended June 30, 2009, a decrease of $342,976. The decrease is partially due to a decrease in the amounts accreted on the discounts recorded on convertible notes originally issued in December 2008 which was offset by interest expense incurred on promissory notes that were issued during fiscal 2010. Interest incurred to related parties was $366,226 during the three months ended June 30, 2011 and $288,042 for the three months ended June 30, 2010, an increase of $78,184 or 27.1%. This increase is primarily related to the issuance of $2,866,879 in promissory notes to our Chief Executive Officer and Director, Cornelis F. Wit during fiscal 2010. The table below provides detail on the significant components of interest expense for the three months ended June 30, 2011 and June 30, 2010.

For the three months ended
Debt Description	June 30, 2011		June 30, 2010		Change $
Accretion of Discount from Derivatives	$	254,198	$	671,477	$	(417,279	)
August 2008 Convertible Notes		47,868		56,595		(8,727	)
December 2008 Convertible Notes		148,991		151,833		(2,842	)
Sept 2009 Secured Convertible Debentures		35,901		41,885		(5,984	)
Dec 2009 Convertible Debentures		44,578		44,578		-0-
General Interest		17,705		7,461		10,244
Related Party Notes		93,376		11,764		81,612
Total	$	642,617	$	985,593	$	(342,976	)

We recorded unrealized losses related to changes in our derivative liabilities associated with the issuance of convertible notes that occurred from fiscal 2008 to 2010. We recorded a net unrealized loss of $54,181 during the three months ended June 30, 2011 compared with a net unrealized gain of $2,407,655 during the three months ended June 30, 2010. The unrealized gains and losses can be attributed to fair value calculations undertaken periodically on the warrant and conversion feature liabilities recorded by us at the time the convertible notes were issued. Accordingly, the warrant and conversion feature liabilities are increased or decreased based on the fair value calculations made at each balance sheet date. During the three month ended June 30, 2011, several factors combined to produce the significant unrealized loss from derivative changes we recorded. These factors include: 1) a significant increase in the share price on the OTC Bulletin Board of our common stock; 2) a marked increase in the calculated volatility used in the valuation model used in determining the fair value of our derivative liabilities; and 3) the maturity date of one of the outstanding convertible notes was extended by two years. This extension increased the fair value of the conversion feature liability underlying that convertible note. These non-cash gains and losses have materially impacted our results of operations during the three months ended June 30, 2011 and during fiscal years 2010, 2009, and 2008 and can be reasonably anticipated to materially affect our net loss or net income in future periods. We are, however, unable to estimate the amount of such income/expense in future periods as the income/expense is partly based on the market price of our common stock at the end of a future measurement date. In addition, in the future if we issue securities which are classified as derivatives we will incur expense and income items in future periods. Investors are cautioned to consider the impact of this non-cash accounting treatment on our financial statements.

The Company recorded arrearages of $51,284 in its 5% Series A Preferred Stock dividends for the three months ended June 30, 2011 and the three months ended June 30, 2010.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate adequate amounts of cash to meet its needs for cash. We have historically experienced negative cash flows and have relied on the proceeds from the sale of debt and equity securities to fund our operations. In addition, we have utilized stock-based compensation as a means of paying for consulting and salary related expenses.

The table provided below summarizes key measures of our liquidity and capital resources:

Liquidity and Capital Resources
(all amounts in USD $)
Summarized Balance Sheet Disclosure
	June 30, 2011			December 31, 2010			Change
Cash	$	134,445		$	1,213,397		$	(1,078,952	)
Accounts Receivable, net of allowance for doubtful accounts		1,191,103			1,031,745			159,358
Prepaids		119,349			97,337			22,012
Current Assets		1,444,897			2,342,479			(897,582	)

Accounts Payable and accrued expenses		1,538,134			1,371,703			166,431
Notes payable, current portion		20,000			12,500			7,500
Notes payable, related parties, current portion		37,500			2,615,000			(2,577,500	)
Patent litigation settlement liability, current portion		737,499			765,089			(27,590	)
Deferred revenue, current portion		4,182,449			4,060,425			122,024
Convertible notes payable, current portion, net of discount		75,000			395,733			(320,733	)
Convertible notes payable, related parties, current portion, net of discount		-0-			2,169,622			(2,169,622	)
Conversion feature liability, related parties, current portion		1,457,230			92,134			1,365,096
Conversion feature liability, current portion		36,546			72			36,474
Warrant liability, related parties		2,454,194			206,760			2,247,434
Warrant liability		548,996			54,388			494,608
Current liabilities		11,087,548			11,482,277			(394,729	)

Working Capital (Deficit)	$	(9,642,651	)	$	(9,139,798	)	$	(502,853	)

Statement of Cash Flows Disclosure
For the six months ended
	June 30, 2011			June 30, 2010
Net cash (used in) operating activities	$	(898,437	)	$	(341,878	)
Net cash used in investing activities		(52,502	)		(218,218	)
Net cash provided by (used in) financing activities		(116,500	)		565,000

Net (decrease) in cash and cash equivalents		(1,078,953	)		(17,874	)

Changes in working capital accounts		(73,791	)		2,243,823
Effect of non-cash transactions on cash and cash equivalents	$	4,066,591		$	(1,281,599	)

Cash and Cash Equivalents

Cash and cash equivalents decreased since December 31, 2010 by $1,078,952 at June 30, 2011. The decrease is comprised of an operating loss of $4,891,236, offset by an increase from non-cash transactions of $4,066,591 offset by a decrease from working capital account changes of $73,791. In addition, during the six months ended June 30, 2011 our investing activities were comprised of purchases of property and equipment of $52,502 and during the six months ended June 30, 2011 we repaid $212,500 in promissory notes and borrowed $96,000 under one promissory note.

During the six months ended June 30, 2011 and during fiscal 2010, our ability to collect on trade receivable improved as compared to fiscal 2009. We saw decreased incidence of customers discontinuing operations and experienced a small amount of uncollectable receivables.

During the remainder of fiscal 2011 we expect to continue to see improved trade receivables collections and not experience any material customer defaults.

In the past, the Company has through extending payments on trade payables managed to improve its working capital and cash position. Additionally, during fiscal 2010 the amounts expended on payroll and operating expenses decreased in connection with a restructuring of our operating costs. The Company has experienced a commensurate decrease in payables and payroll related accruals and expects these trends to continue during the remainder of fiscal 2011.

Capital Expenditures

We are not currently bound by any long or short-term agreements for the purchase or lease of capital expenditures. Any amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately service any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future.

Presently, we have approximately $200,000 planned for capital expenditures to further develop the Company’s infrastructure to allow for growth in our operations over the next nine months. We expect to fund these capital expenditure needs through a combination of vendor-provided financing, the use of operating or capital equipment leases and cash provided from operations.

Contractual Obligations

The following table sets forth our contractual obligations during the next five years as of June 30, 2011:

Contractual Obligations			Payments Due by Period
	Total		Less than 1 year			1-2 Years			2-3 Years			3-5 Years
Promissory Notes (1)	$	3,670,666	$	20,000	(2)	$	214,300	(3)	$	569,487	(4)	$	2,866,879
Convertible Notes		9,665,000		75,000	(6)		-0-			9,590,000	(7)		-0-
Operating Lease Obligations (8)		1,225,959		257,733			386,378			194,738			387,110
Patent Licensing Fees (9)		2,537,499		737,499			450,000			450,000			900,000
Total	$	17,099,124	$	1,090,232		$	1,050,678		$	10,804,225		$	4,153,989

Amounts do not include interest to be paid.

Includes $20,000 of 12% notes payable that mature in December 2011.

Includes $111,800 of 12% notes payable that mature in July 2012; $37,500 of 12% notes payable that mature in April 2012; $20,000 of 12% notes payable that mature on December 2012; and $45,000 of 12% notes payable that mature in October 2012.

Includes $137,500 of 12% notes payable that mature in April 2013; and $431,987 of 10% notes payable that mature in January 2013.

Includes a $2,866,879 12% note payable that matures in April 2014.

Includes $75,000 of 10% convertible notes currently in default and due that are convertible into shares of common stock at the option of the holder at a conversion rate of $1.25 per share.

Includes $1,920,000 in 10% convertible notes that mature in August 2013 and $4,980,000 in 12% convertible notes that mature in December 2013 and $1,200,000 in 12% convertible notes that mature in March 2013; and $1,490,000 in convertible notes that mature in December 2013.

Includes office lease obligations for our headquarters in Fort Lauderdale, for our regional operating office in New Jersey, our R & D office in England, our European headquarters in Bonn, Germany and our co-location and disaster recovery computer service centers in Cincinnati, Ohio and Fort Lauderdale, Florida.

Relates to guaranteed minimum payments owed in connection with our settlement of a patent infringement lawsuit brought against the Company by DataSci, LLC.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Debt Obligations

We are currently in arrears on principal and interest payments owed totaling $165,947 on our 10% Convertible Notes that were issued in 1998. We were in default effective January 30, 2002.

On February 1, 2011, the Company issued a promissory note for $137,500 to Noesis International Holdings, the parent company of Noesis Capital Corp., the Company’s Placement Agent for several equity and debt transactions from 1999 to 2007 and a significant shareholder in the Company. The promissory note bears interest at 12% per annum payable April 1, 2013and replaces a promissory note in the same principal amount that matured on January 31, 2011.

On March 31, 2011, the Company issued a promissory note in the principal amount of $2,866,879 to our Chief Executive Officer, Cornelis F. Wit. The promissory note bears interest at 12% per annum and is due on April 1, 2014. The promissory note consolidates the principal amounts owed under several promissory notes originally issued during 2010. The promissory note is comprised of the following amounts received on the following dates:

vi.

Promissory Note issued on April 13, 2010 with a principal amount of $450,000 with a maturity date of December 31, 2010.

vii.

Promissory Note issued on June 29, 2010 with a principal amount of $115,000 with a maturity date of December 31, 2010.

viii.

Promissory Note issued on September 30, 2010 with a principal amount of $695,000 with a maturity date of December 31, 2010.

ix.

Promissory Note issued on December 31, 2010 with a principal amount of $1,197,500 with a maturity date of December 31, 2010.

Promissory Note issued on December 31, 2010 with a principal amount of $409,379 with a maturity date of April 01, 2012.

On May 13, 2011, the Company issued a note payable with a principal amount owed of $96,000 to our Chief Executive Officer, Cornelis F. Wit. The note accrues interest at a rate of 12% per annum and has a maturity date of January 1, 2013.

During the next twelve months the following debts mature: $75,000 of 10% convertible notes currently in default and due; $20,000 from a promissory note, held by our Chief Technology Officer, Randall G. Smith, that matures in December 2011 and $37,500 from a promissory note held by an investor that matures in April 2012.

Sources of Liquidity and Capital Resources

Because of the losses we have experienced from operations we have needed to continue utilizing the proceeds from the sale of debt and equity securities to fund our working capital needs. We have used a combination of equity financing, short-term bridge loans and long-term loans to fund our working capital needs, if any. Other than our revenues, current capital and capital we may raise from future debt or equity offerings or short-term bridge loans, we do not have any additional sources of working capital.

Since 2008, the Company has utilized the proceeds of convertible debentures, convertible notes and promissory notes (“Debt Capital”) to satisfy its working capital and capital expenditure needs. During 2008 and 2009 we raised $10,035,000 in the form of convertible debentures that remain outstanding. Approximately 96% of that Debt Capital was issued to officers, directors or significant senior managers of the Company, including debentures totaling $8,660,000 to our Chief Executive Officer. During 2010 we raised $2,886,879 from promissory notes to our Chief Executive Officer. In addition, we issued a $20,000 promissory note to our Chairman and Chief Technology Officer during 2010.

In November 2010, we issued 250,000 shares of our Series D Preferred Stock to our Chief Executive Officer, Cornelis F. Wit in exchange for the conversion of $1,000,000 of the Company’s convertible notes.

We may continue to require substantial funds to continue our research and development activities and to market, sell and commercialize our technology. We may need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our research and development activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; the cost of filing, prosecuting, defending and enforcing intellectual property rights; and other changes in economic, regulatory or competitive conditions in our planned business. Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the research and development programs relating to our technology can be conducted at projected costs and that progress towards broader commercialization of our technology will be timely and successful. There can be no assurance that changes in our research and development plans or other events will not result in accelerated or unexpected expenditures.

During the second half of 2010, the Company made material changes to its cost structure including reducing commitments for financial advisory and product development consulting arrangements. We have looked closely at staffing costs and attempted to ensure that our overall salary levels are structured around the current and projected business development and contract levels expected for the next 12 months.

While the Company has not sought capital from venture capital or private equity sources we believe that those sources of capital remain available although possibly under terms and conditions that might be disadvantageous to existing investors.

To satisfy our capital requirements, including ongoing future operations, we may seek to raise additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development programs, and our business operations. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock or result in increased interest expense in future periods. Further, there can be no assurance that even if such additional capital is obtained or the planned cost reductions are implemented, that we will achieve positive cash flow or profitability or be able to continue as a business.

While several of our officers and directors have historically, either personally or through funds with which they are affiliated, provided substantial capital either in the form of debt or equity financing there can be no assurance that they will continue to provide any such funding to us on favorable terms or at all.

Our ability to continue in existence is dependent on our having sufficient financial resources to bring products and services to market. As a result of our historical operating losses, negative cash flows and accumulated deficits for the periods ending June 30, 2011, there is substantial doubt about our ability to continue as a going concern. In addition, our auditors Webb & Company, P.A., included language which qualified their opinion regarding our ability to continue as a going concern in their report dated March 29, 2011 regarding our audited financial statements for the year ended December 31, 2010.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to the Consolidated Financial Statements describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, our Management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, our Management believes that our consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States (GAAP), and present a meaningful presentation of our financial condition and results of operations.

Our Management believes that the following are our critical accounting policies:

ASSET IMPAIRMENT

Asset Acquisitions and Intangible Assets

We account for asset acquisitions in accordance with ASC 350, Intangibles- Goodwill and Other. The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of an asset acquisition.

Long Lived Assets

DEFERRED REVENUE

REVENUE RECOGNITION POLICY

OmniComm’s revenue model is transaction-based and can be implemented either as an ASP (application service provider) or licensed for implementation by a customer such as a pharmaceutical company. Revenues are derived from the set-up of clinical trial engagements; licensing arrangements, fees earned for hosting our clients’ data and projects, on-going maintenance fees incurred throughout the duration of an engagement; fees for report writing and project change orders. The clinical trials that are conducted using our EDC Applications can last from a few months to several years. Most of the fees associated with our product including post-setup customer support in the form of maintenance charges are recognized ratably over the term of clinical trial projects. Cost of sales is primarily comprised of programmer salaries and taxes and is expensed as incurred.

The Company recognizes sales, for both financial statement and tax purposes in accordance with ASC 605- Revenue Recognition and ASC 605.985, Software Industry Revenue Recognition. ASC 605 requires that revenues be recognized ratably over the life of a contract. The Company will periodically record deferred revenues relating to advance payments in contracts. Under its licensing arrangement the Company recognizes revenue pursuant to ASC 605.985. Under these arrangements the Company recognizes revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the service has been provided to the customer and/or delivery has occurred; (3) the collection of fees is probable; and (4) the fee is fixed or determinable. ASC 605.985, as amended, requires revenue earned on software arrangements involving multiple elements to be allocated to each element based on the relative fair values of the elements. We have analyzed each element in our multiple element arrangements and determined that we have sufficient vendor-specific objective evidence (“VSOE”) to allocate revenues to license updates and product support. License revenues are recognized on delivery if the other conditions of ASC 605.985 are satisfied. License updates and product support revenue is recognized ratably over the term of the arrangement. In arrangements where term licenses are bundled with license updates and product support and such revenue is recognized ratably over the term of the arrangement, we allocate the revenue to license revenue and to license updates and product support revenue based on the VSOE of fair value for license updates and product support revenue on perpetual licenses of similar products.

STOCK BASED COMPENSATION.

The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions.

ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Income. The Company currently uses the American Binomial option pricing model to determine grant date fair value.

EFFECT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

During fiscal 2011, we adopted the following new accounting pronouncements:

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements that have been issued since the filing of our Form 10K for the year ended December 31, 2010 to determine their impact, if any, on our financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, for the period ended June 30, 2011, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) were effective such that the information relating to the Company, including our consolidating subsidiaries, required to be disclosed by the Company in reports that it files or submits under the Exchange Act (1) was recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) was accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls over Financial Reporting

There were no significant changes in the Company’s internal controls over financial reporting or in other factors that could significantly affect these controls over financial reporting that occurred during the three months ended June 30, 2011 and up to the filing date of this quarterly report on Form 10-Q. There were no significant deficiencies or material weaknesses, and therefore there were no corrective actions taken.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Not applicable for a smaller reporting company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the period ended June 30, 2011, the Company issued 400,000 shares of common stock to an employee in lieu of salary and recorded $40,000 as salary expense. The shares were issued pursuant to an exemption from registration under the Securities Act of 1933 in reliance on the exemptions provided by Section 4(2) of that act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. REMOVED AND RESERVED.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

EXHIBIT NO.	DESCRIPTION
10.45	Promissory note dated May 13, 2011 to Cornelis F. Wit
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
31.2	Certification of Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities and Exchange Act of 1934, as amended.
32.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation
101.DEF*	XBRL Taxonomy Extension Definition
101.LAB*	XBRL Taxonomy Extension Label
101.PRE*	XBRL Taxonomy Extension Presentation

*In accordance with Rule 406T of regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OmniComm Systems, Inc.


By:	/s/ Cornelis F. Wit	By:	/s/ Ronald T. Linares
	Cornelis F. Wit		Ronald T. Linares,
	Director, Chief Executive Officer and President (Principal Executive Officer)		Executive Vice President of Finance, Chief Financial and Accounting Officer (Principal Financial and Accounting Officer)
Date:	August 5, 2011	Date:	August 5, 2011